Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 1
1993 1
1995 2
1996 3
1997 3
1998 9
1999 7
2000 12
2001 9
2002 24
2003 19
2004 32
2005 22
2006 29
2007 52
2008 70
2009 96
2010 130
2011 161
2012 164
2013 190
2014 183
2015 183
2016 151
2017 173
2018 170
2019 179
2020 201
2021 195
2022 172
2023 161
2024 150
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,681 results

Results by year

Filters applied: Free full text. Clear all
Page 1
Synthesis and Anticancer Evaluation of O-Alkylated (E)-Chalcone Derivatives: A Focus on Estrogen Receptor Inhibition.
Al-Ghamdi AR, Ahmed WU, Al-Wabli RI, Al-Mutairi MS, Rahman AFMM. Al-Ghamdi AR, et al. Int J Mol Sci. 2025 Jan 20;26(2):833. doi: 10.3390/ijms26020833. Int J Mol Sci. 2025. PMID: 39859546 Free PMC article.
Cancer remains a leading cause of morbidity and mortality worldwide, highlighting the urgent need for novel therapeutic agents. ...In silico analyses further highlighted the favorable pharmacokinetic properties of compound 4q, underscoring its potential as a selective t
Cancer remains a leading cause of morbidity and mortality worldwide, highlighting the urgent need for novel therapeutic agents. ...In
PD-L1 monoclonal antibody alleviated MI injury of left ventricular function via modulating CD47/SHP2/SIRPα/SYK/FcγR signalings in tumor associated macrophages.
Kong D, Chen Y, Yin Y, Liu Z, Yang F, Li X, Shen D, Zhang J. Kong D, et al. Sci Rep. 2025 Jan 17;15(1):2303. doi: 10.1038/s41598-024-85065-w. Sci Rep. 2025. PMID: 39824849 Free PMC article.
Cardiac function was assessed by ultrasound. Heart tissue and breast cancer tumor samples were isolated, and the content of cGAMP was measured using LC-MS/MS. ...In the in vivo experiments, ultrasound examination showed that PD-L1 mAb improved cardiac function in mi …
Cardiac function was assessed by ultrasound. Heart tissue and breast cancer tumor samples were isolated, and the content of cG …
Novel anti-HER2 ADCs vs dual anti-HER2 antibody for HER2-positive metastatic breast cancer failed to tyrosine kinase inhibitor.
Li F, Li J, Ji C, Wu S, Zhang S, Wang T, Bian L, Jiang Z. Li F, et al. Oncologist. 2025 Jan 17;30(1):oyae144. doi: 10.1093/oncolo/oyae144. Oncologist. 2025. PMID: 39786451 Free PMC article.
BACKGROUND: Both novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) and pertuzumab and trastuzumab (HP) combined with chemotherapy(C) regimens are the choice of treatment for HER2 positive metastatic breast cancer (MBC) after …
BACKGROUND: Both novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) and pertuzumab and trastuzumab ( …
Discovery of PPAR Alpha Lipid Pathway Modulators That Do Not Bind Directly to the Receptor as Potential Anti-Cancer Compounds.
Al Subait A, Alghamdi RH, Ali R, Alsharidah A, Huwaizi S, Alkhodier RA, Almogren AS, Alzomia BA, Alaskar A, Boudjelal M. Al Subait A, et al. Int J Mol Sci. 2025 Jan 16;26(2):736. doi: 10.3390/ijms26020736. Int J Mol Sci. 2025. PMID: 39859448 Free PMC article.
Peroxisome proliferator-activated receptors (PPARs) are considered good drug targets for breast cancer because of their involvement in fatty acid metabolism that induces cell proliferation. ...Our findings suggest that these two compounds have opposite effects invol …
Peroxisome proliferator-activated receptors (PPARs) are considered good drug targets for breast cancer because of their involv …
Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti-cancer agents.
Sunaga T, Okada T, Iso Y, Ebato M, Toshida T, Nawata S, Suzuki H, Kogo M. Sunaga T, et al. ESC Heart Fail. 2025 Jan 13. doi: 10.1002/ehf2.15204. Online ahead of print. ESC Heart Fail. 2025. PMID: 39801274 Free article.
In particular, treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (OR, 1.69; 95% CI 1.39-2.07), taxane (OR, 2.95; 95% CI 2.11-4.12), anthracyclines (OR, 1.86; 95% CI 1.19-2.90) and fluorouracil agents (OR, 1.65; 95% CI 1.18 …
In particular, treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (OR, 1.69; 95% CI …
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.
Wilding B, Woelflingseder L, Baum A, Chylinski K, Vainorius G, Gibson N, Waizenegger IC, Gerlach D, Augsten M, Spreitzer F, Shirai Y, Ikegami M, Tilandyová S, Scharn D, Pearson MA, Popow J, Obenauf AC, Yamamoto N, Kondo S, Opdam FL, Bruining A, Kohsaka S, Kraut N, Heymach JV, Solca F, Neumüller RA. Wilding B, et al. Cancer Discov. 2025 Jan 13;15(1):119-138. doi: 10.1158/2159-8290.CD-24-0306. Cancer Discov. 2025. PMID: 39248702 Free PMC article.
Mutations in ERBB2 (encoding HER2) occur in 2% to 4% of non-small cell lung cancer (NSCLC) and confer poor prognosis. ERBB-targeting tyrosine kinase inhibitors, approved for treating other HER2-dependent cancers, are ineffective in HER2-mutant NSCLC du …
Mutations in ERBB2 (encoding HER2) occur in 2% to 4% of non-small cell lung cancer (NSCLC) and confer poor prognosis. ERBB-targeting …
Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs).
He Q, Lin J, Mo C, Li G, Lu J, Sun Q, Cao L, Gan H, Sun Q, Yao J, Lian S, Wang W. He Q, et al. Front Pharmacol. 2025 Jan 9;15:1463520. doi: 10.3389/fphar.2024.1463520. eCollection 2024. Front Pharmacol. 2025. PMID: 39850566 Free PMC article. Review.
The emergence of targeted anti-tumor drugs has significantly prolonged the lifespan and improved the prognosis of cancer patients. Among these drugs, vascular endothelial growth factor (VEGF) inhibitors, particularly novel small molecule tyrosine kinase
The emergence of targeted anti-tumor drugs has significantly prolonged the lifespan and improved the prognosis of cancer patients. Am …
Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer.
Mahdi AF, Ashfield N, Crown J, Collins DM. Mahdi AF, et al. Int J Mol Sci. 2025 Jan 8;26(2):460. doi: 10.3390/ijms26020460. Int J Mol Sci. 2025. PMID: 39859174 Free PMC article.
HER2-positive/oestrogen receptor-positive (HER2+/ER+) represents a unique breast cancer subtype. The use of individual HER2- or ER-targeting agents can lead to the acquisition of therapeutic resistance due to compensatory receptor crosstalk. New drug combinations ta …
HER2-positive/oestrogen receptor-positive (HER2+/ER+) represents a unique breast cancer subtype. The use of individual HER2- o …
PNMA1 is a novel immune modulator and therapeutic target in hepatocellular carcinoma linked to bile acid metabolism.
Chu H, Shan Y, Jiang C, Zhong Y, Liu Z, Fang X, Yang Z. Chu H, et al. Sci Rep. 2025 Jan 3;15(1):738. doi: 10.1038/s41598-024-84368-2. Sci Rep. 2025. PMID: 39754028 Free PMC article.
Notably, PNMA1 has emerged as a promising therapeutic target for tyrosine kinase inhibitors, as confirmed by reduced IC50 values and molecular docking. Experimental knockdown of PNMA1 hindered HepG2 cell proliferation and migration. Furthermore, PNMA1 is a pi …
Notably, PNMA1 has emerged as a promising therapeutic target for tyrosine kinase inhibitors, as confirmed by reduced IC …
Folic Acid-Modified Milk Exosomes Delivering c-Kit siRNA Overcome EGFR-TKIs Resistance in Lung Cancer by Suppressing mTOR Signaling and Stemness.
Xu Z, Wang L, Tu L, Liu T, Zhang Y, He Y, Xiao G, Ouyang G, Ma X, Luo F. Xu Z, et al. Int J Biol Sci. 2025 Jan 1;21(1):382-399. doi: 10.7150/ijbs.99954. eCollection 2025. Int J Biol Sci. 2025. PMID: 39744423 Free PMC article.
The EGFR-TKIs (epidermal growth factor receptor-tyrosine kinases inhibitors) offer significant benefits to lung cancer patients with sensitive EGFR mutations; however, the development of acquired resistance poses a significant challenge and leads to poor prog …
The EGFR-TKIs (epidermal growth factor receptor-tyrosine kinases inhibitors) offer significant benefits to lung cancer
Metastatic brain tumors: from development to cutting-edge treatment.
Tanzhu G, Chen L, Ning J, Xue W, Wang C, Xiao G, Yang J, Zhou R. Tanzhu G, et al. MedComm (2020). 2024 Dec 20;6(1):e70020. doi: 10.1002/mco2.70020. eCollection 2025 Jan. MedComm (2020). 2024. PMID: 39712454 Free PMC article. Review.
This review focuses on BM originating from lung cancer and breast cancer. We briefly overview the history and epidemiology of BM, as well as the current diagnostic and treatment paradigms. ...BM is primarily treated with a comprehensive approach, including lo …
This review focuses on BM originating from lung cancer and breast cancer. We briefly overview the history and epidemiol …
Tyrosine Kinase Inhibitor Induced Proteinuria - A Review.
Gayathri JS, Krishna SS, Rakesh MP. Gayathri JS, et al. Drug Res (Stuttg). 2025 Jan;75(1):5-11. doi: 10.1055/a-2423-3533. Epub 2024 Oct 15. Drug Res (Stuttg). 2025. PMID: 39406370 Free article. Review.
Tyrosine Kinase inhibitor (TKI) is a class of drugs that interfere with protein kinases' signal transduction pathways through an array of inhibitory mechanisms. ...Hence, tyrosine kinase inhibitors (TKIs) are frequently employed as anti-neoplast
Tyrosine Kinase inhibitor (TKI) is a class of drugs that interfere with protein kinases' signal transduction pathways through
The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy.
Zhang F, Wang S, Yu C, Jin W, He D, Hu X, Wang S, Zhu T. Zhang F, et al. BMC Cancer. 2024 Dec 30;24(1):1585. doi: 10.1186/s12885-024-13377-1. BMC Cancer. 2024. PMID: 39734198 Free PMC article.
We sought to evaluate earlier the subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy, and identify the risk factors related to subclinical myocardiotoxicity. METHODS: In our study, 40 breast cancer
We sought to evaluate earlier the subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 …
Neratinib enhances the efficacy of CDK4/6 inhibitor plus endocrine therapy in HR(+)/HER2-low breast cancer cell line ZR-75-1 via hsa-miR-23a-5p.
Chen L, Ye L, Liang Y, Luo W, Zuo Q, Huang P, Hu Y, Dai Y, Wu Y, Guo Q, Chen Q. Chen L, et al. Sci Rep. 2024 Dec 28;14(1):31062. doi: 10.1038/s41598-024-82137-9. Sci Rep. 2024. PMID: 39730704 Free PMC article.
HR(+)/HER2-low breast cancer is a significant subgroup of conventional HR(+)/HER2-negative breast cancer, and combination of CDK4/6 inhibitor and endocrine therapy is the standard first-line and second-line treatments for advanced HR(+)/HER2-low bre
HR(+)/HER2-low breast cancer is a significant subgroup of conventional HR(+)/HER2-negative breast cancer, and co …
Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression.
Altıntaş YE, Kınıkoğlu O, Yıldız A, Işık D, Özkerim U, Öksüz S, Tüylü TB, Sürmeli H, Turan N, Odabaş H. Altıntaş YE, et al. Medicina (Kaunas). 2024 Dec 16;60(12):2069. doi: 10.3390/medicina60122069. Medicina (Kaunas). 2024. PMID: 39768949 Free PMC article.
Background and Objectives: Metastatic breast cancer (MBC), particularly the HER2-positive subtype, represents a significant clinical challenge, with approximately 20-25% of breast cancer cases demonstrating HER2 overexpression. ...
Background and Objectives: Metastatic breast cancer (MBC), particularly the HER2-positive subtype, represents a significant cl …
Protein tyrosine phosphatase PTPH1 potentiates receptor tyrosine kinase HER2 oncogenesis via a PDZ-coupled and phosphorylation-driven scaffold.
Qi X, Wang F, Thomas L, Ma S, Palen K, Lu Y, Sheinin Y, Gershan J, Fu L, Chen G. Qi X, et al. Am J Cancer Res. 2024 Dec 15;14(12):5734-5751. doi: 10.62347/JRHH6478. eCollection 2024. Am J Cancer Res. 2024. PMID: 39803648 Free PMC article.
Here, we reported that protein tyrosine phosphatase H1 (PTPH1) is a scaffold protein for receptor tyrosine kinase (HER2) to potentiate breast tumorigenesis. ...PTPH1 protein levels are higher in HER2(+) breast cancer in which their phosph …
Here, we reported that protein tyrosine phosphatase H1 (PTPH1) is a scaffold protein for receptor tyrosine kinase (HER2 …
Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatments.
Guglielmi G, Zamagni C, Del Re M, Danesi R, Fogli S. Guglielmi G, et al. Eur J Pharmacol. 2024 Dec 15;985:177076. doi: 10.1016/j.ejphar.2024.177076. Epub 2024 Oct 30. Eur J Pharmacol. 2024. PMID: 39486766 Free article. Review.
Understanding the capability of a drug to penetrate the blood-brain barrier (BBB) is an unmet medical need in patients with positive human epidermal growth factor receptor 2 (HER2 positive) and brain metastases. The National Comprehensive Cancer Network (NCCN) guidelines r …
Understanding the capability of a drug to penetrate the blood-brain barrier (BBB) is an unmet medical need in patients with positive human e …
Targeting RTKs/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials.
Mehta K, Hegde M, Girisa S, Vishwa R, Alqahtani MS, Abbas M, Shakibaei M, Sethi G, Kunnumakkara AB. Mehta K, et al. Mil Med Res. 2024 Dec 12;11(1):76. doi: 10.1186/s40779-024-00582-z. Mil Med Res. 2024. PMID: 39668367 Free PMC article. Review.
The extensive heterogeneity and the limited availability of effective targeted therapies contribute to the challenging prognosis and restricted survival observed in triple-negative breast cancer (TNBC). Recent research indicates the aberrant expression of diverse …
The extensive heterogeneity and the limited availability of effective targeted therapies contribute to the challenging prognosis and restric …
Apatinib and trastuzumab-based chemotherapy for heavily treated primary trastuzumab-resistant metastatic breast cancer.
Chen X, Huang J, Xie X, Chen L, Lan X, Song L, Bai X, Du C. Chen X, et al. J Cancer Res Ther. 2024 Dec 1;20(7):1991-1996. doi: 10.4103/jcrt.jcrt_979_24. Epub 2025 Jan 10. J Cancer Res Ther. 2024. PMID: 39792408 Free article.
All patients had progressed on 2 anti-HER2 treatments, including trastuzumab and small molecular tyrosine kinase inhibitors. We evaluated tumor response and safety profiles to ATBC over a median follow-up time of 34.5 months. RESULTS: A total of 198 consecuti …
All patients had progressed on 2 anti-HER2 treatments, including trastuzumab and small molecular tyrosine kinase inhibitors
Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors.
Xu C, Lian B, Ou J, Wang Q, Wang W, Wang K, Wang D, Song Z, Liu A, Yu J, Zhong W, Wang Z, Zhang Y, Liu J, Zhang S, Cai X, Liu A, Li W, Mao L, Zhan P, Liu H, Lv T, Miao L, Min L, Chen Y, Yuan J, Wang F, Jiang Z, Lin G, Huang L, Pu X, Lin R, Liu W, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Xue J, Guo H, Chu Q, Meng R, Wu J, Zhang R, Zhou J, Zhu Z, Li Y, Qiu H, Xia F, Lu Y, Chen X, Ge R, Dai E, Han Y, Pan W, Pang F, Huang J, Wang K, Wu F, Xu B, Wang L, Zhu Y, Lin L, Xie Y, Lin X, Cai J, Xu L, Li J, Jiao X, Li K, Wei J, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Huang J, Feng Y, Zhang Y, Sun P, Wang H, Ye M, Wang Z, Hao Y, Wang Z, Wan B, Lv D, Zhai Z, Yang S, Kang J, Zhang J, Zhang C, Shi L, Wang Y, Li B, Zhang Z, Li Z, Liu Z, Yang N, Wu L, Wang H, Jin G, Wang G, Wang J, Fang M, Fang Y, Li Y, Wang X, Chen J, Zhang Y, Zhu X, Shen Y, Ma S, Wang B, Si L, Lu Y, Li Z, Fang W, Song Y. Xu C, et al. Glob Med Genet. 2024 Sep 16;11(4):330-343. doi: 10.1055/s-0044-1790230. eCollection 2024 Dec. Glob Med Genet. 2024. PMID: 39583123 Free PMC article. Review.
The fibroblast growth factor receptor (FGFR) is a crucial receptor tyrosine kinase involved in essential biological processes, including growth, development, and tissue repair. However, FGFR gene mutations, including amplification, fusion, and mutation, can disrupt …
The fibroblast growth factor receptor (FGFR) is a crucial receptor tyrosine kinase involved in essential biological processes, …
"Oh when's your treatment ending?" "Never!" The unmet needs of cancer patients treated with immunological, biological and precision therapies: A qualitative interview study.
Crowe L, Brown MC, Lecouturier J, Greystoke A, Bojke A, Bojke R, Richardson J, Wells M, Ezeala E, Carter L, Sharp L, Todd A. Crowe L, et al. Eur J Oncol Nurs. 2024 Dec;73:102696. doi: 10.1016/j.ejon.2024.102696. Epub 2024 Sep 23. Eur J Oncol Nurs. 2024. PMID: 39500062 Free article.
PURPOSE: To explore the unmet supportive care needs of patients with advanced cancer receiving immuno-, biological and precision (IBP) therapies. METHODS: We conducted semi-structured interviews with: (1) adults diagnosed with advanced cancer (lung, colorectal, ovar …
PURPOSE: To explore the unmet supportive care needs of patients with advanced cancer receiving immuno-, biological and precision (IBP …
Synthesis and in vitro exploration of the 8-carbo substituted 5-methoxyflavones as anti-breast and anti-lung cancer agents targeting protein kinases (VEGFR-2 & EGFR).
Nkoana JK, More GK, Mphahlele MJ, Elhenawy AA. Nkoana JK, et al. Bioorg Chem. 2024 Dec;153:107875. doi: 10.1016/j.bioorg.2024.107875. Epub 2024 Oct 10. Bioorg Chem. 2024. PMID: 39396454 Free article.
Compounds 3b, 3c, 3d, 4a and 4b exhibited strong activity against the human breast (MCF-7) cancer cell line (IC(50) = 13.68 0.72, 16.91 0.40, 13.63 0.36, 14.66 0.47 and 12.26 0.45 muM, respectively) and lung (A549) cancer cell line (IC(50) = 15.38 0.33, 10.00 …
Compounds 3b, 3c, 3d, 4a and 4b exhibited strong activity against the human breast (MCF-7) cancer cell line (IC(50) = 13.68 0. …
The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2.
Dolatabadi B, Peymani M, Rouhi L, Salehzadeh A, Hushmandi K, Hashemi M. Dolatabadi B, et al. Mol Cell Probes. 2024 Dec;78:101985. doi: 10.1016/j.mcp.2024.101985. Epub 2024 Oct 8. Mol Cell Probes. 2024. PMID: 39369912 Free article.
In addition, we investigated the therapeutic potential of lapatinib as an inhibitor of these receptors in various cancer types. METHODS: RNAseq data for prevalent cancers were downloaded from The Cancer Genome Atlas (TCGA). ...CONCLUSION: Our results indicate an upr …
In addition, we investigated the therapeutic potential of lapatinib as an inhibitor of these receptors in various cancer types. METHO …
Clinical research progress of fruquintinib in the treatment of malignant tumors.
Zhao S, Wang W, Li J, Li Z, Liu Z, Zhang S, Chen Z, Wang H, Wang X, Wang J. Zhao S, et al. Invest New Drugs. 2024 Dec;42(6):612-622. doi: 10.1007/s10637-024-01476-6. Epub 2024 Oct 1. Invest New Drugs. 2024. PMID: 39352649 Free PMC article.
Fruquintinib, an anti-angiogenic small molecule drug developed independently in China, functions as a potent tyrosine kinase inhibitor with high selectivity. It effectively curtails tumor growth by binding to and inhibiting VEGFR-1, VEGFR-2, and VEGFR-3. ...It has s …
Fruquintinib, an anti-angiogenic small molecule drug developed independently in China, functions as a potent tyrosine kinase i …
Potential Drug Synergy Through the ERBB2 Pathway in HER2+ Breast Tumors.
Rojas-Salazar Y, Gómez-Montañez E, Rojas-Salazar J, de Anda-Jáuregui G, Hernández-Lemus E. Rojas-Salazar Y, et al. Int J Mol Sci. 2024 Nov 29;25(23):12840. doi: 10.3390/ijms252312840. Int J Mol Sci. 2024. PMID: 39684551 Free PMC article.
HER2-positive (HER2+) breast cancer is characterized by the overexpression of the ERBB2 (HER2) gene, which promotes aggressive tumor growth and poor prognosis. ...This study aims to explore potential drug synergies by analyzing gene-drug interactions and combination …
HER2-positive (HER2+) breast cancer is characterized by the overexpression of the ERBB2 (HER2) gene, which promotes aggressive …
c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity.
Jabbarzadeh Kaboli P, Roozitalab G, Farghadani R, Eskandarian Z, Zerrouqi A. Jabbarzadeh Kaboli P, et al. Front Immunol. 2024 Nov 27;15:1498391. doi: 10.3389/fimmu.2024.1498391. eCollection 2024. Front Immunol. 2024. PMID: 39664377 Free PMC article. Review.
Cellular mesenchymal-epithelial transition factor (c-MET), also known as hepatocyte growth factor receptor (HGFR), is a crucial receptor tyrosine kinase implicated in various solid tumors, including lung, breast, and liver cancers. ...Despite the challenges a …
Cellular mesenchymal-epithelial transition factor (c-MET), also known as hepatocyte growth factor receptor (HGFR), is a crucial receptor …
RSK1 dependency in FLT3-ITD acute myeloid leukemia.
Kong T, Laranjeira ABA, Letson CT, Yu L, He F, Jayanthan A, Los G, Dunn SE, Challen GA, Oh ST. Kong T, et al. Blood Cancer J. 2024 Nov 26;14(1):207. doi: 10.1038/s41408-024-01187-4. Blood Cancer J. 2024. PMID: 39592591 Free PMC article.
Internal tandem duplications (ITD) in fms-like tyrosine kinase 3 (FLT3) represent the most common genetic alteration in de novo acute myeloid leukemia (AML). ...Importantly, multivariate analysis revealed heightened expression of RPS6KA1 and USP1 to be associated wi …
Internal tandem duplications (ITD) in fms-like tyrosine kinase 3 (FLT3) represent the most common genetic alteration in de nov …
Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy-A Narrative Review.
Kędzierska M, Bańkosz M. Kędzierska M, et al. J Clin Med. 2024 Nov 25;13(23):7131. doi: 10.3390/jcm13237131. J Clin Med. 2024. PMID: 39685591 Free PMC article. Review.
Modern oncology increasingly relies on the role of proteins as key components in cancer diagnosis, prognosis, and targeted therapy. This review examines advancements in protein biomarkers across several cancer types, including breast cancer, lung ca
Modern oncology increasingly relies on the role of proteins as key components in cancer diagnosis, prognosis, and targeted therapy. T …
Rhodanine-Piperazine Hybrids as Potential VEGFR, EGFR, and HER2 Targeting Anti-Breast Cancer Agents.
Szczepański J, Khylyuk D, Korga-Plewko A, Michalczuk M, Mańdziuk S, Iwan M, Trotsko N. Szczepański J, et al. Int J Mol Sci. 2024 Nov 19;25(22):12401. doi: 10.3390/ijms252212401. Int J Mol Sci. 2024. PMID: 39596465 Free PMC article.
Breast cancer is one of the most common malignancies affecting women worldwide, with a significant need for novel therapeutic agents to target specific molecular pathways involved in tumor progression. ...These findings highlight the potential of rhodanine-piperazin
Breast cancer is one of the most common malignancies affecting women worldwide, with a significant need for novel therapeutic
New naphthalene-linked pyrazoline-thiazole hybrids as prominent antilung and antibreast cancer inhibitors.
Çiftçi H, Otsuka M, Fujita M, Sever B. Çiftçi H, et al. Turk J Chem. 2024 Nov 18;48(6):856-866. doi: 10.55730/1300-0527.3704. eCollection 2024. Turk J Chem. 2024. PMID: 39780846 Free PMC article.
The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), pioneer members of the receptor tyrosine kinase subfamily, are frequently mutated and/or overexpressed in several types of human cancers, including nonsmall cell lung …
The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), pioneer members of the receptor tyrosine
Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations.
Wang W, Lian B, Xu C, Wang Q, Li Z, Zheng N, Liu A, Yu J, Zhong W, Wang Z, Zhang Y, Liu J, Zhang S, Cai X, Liu A, Li W, Mao L, Zhan P, Liu H, Lv T, Miao L, Min L, Chen Y, Yuan J, Wang F, Jiang Z, Lin G, Huang L, Pu X, Lin R, Liu W, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Xue J, Guo H, Chu Q, Meng R, Liu X, Wu J, Zhang R, Zhou J, Zhu Z, Li Y, Qiu H, Xia F, Lu Y, Chen X, Feng J, Ge R, Dai E, Han Y, Pan W, Pang F, Huang X, Hu M, Hao Q, Wang K, Wu F, Song B, Xu B, Wang L, Zhu Y, Lin L, Xie Y, Lin X, Cai J, Xu L, Li J, Jiao X, Li K, Wei J, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Huang J, Feng Y, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Hao Y, Wang Z, Wan B, Lv D, Yang S, Kang J, Zhang J, Zhang C, Li W, Fu J, Wu L, Lan S, Ou J, Shi L, Zhai Z, Wang Y, Li B, Zhang Z, Wang K, Ma X, Li Z, Liu Z, Yang N, Wu L, Wang H, Jin G, Wang G, Wang J, Shi H, Fang M, Fang Y, Li Y, Wang X, Chen J, Zhang Y, Zhu X, Shen Y, Ma S, Wang B, Song Y, Song Z, Fang W, Lu Y, Si L. Wang W, et al. Innovation (Camb). 2024 Oct 18;5(6):100661. doi: 10.1016/j.xinn.2024.100661. eCollection 2024 Nov 4. Innovation (Camb). 2024. PMID: 39529955 Free PMC article. Review.
When the BRAF gene mutates, it can lead to abnormal activation of the signaling pathway, which promotes cell proliferation, inhibits cell apoptosis, and ultimately contributes to the occurrence and development of cancer. BRAF mutations are widely present in various cancers …
When the BRAF gene mutates, it can lead to abnormal activation of the signaling pathway, which promotes cell proliferation, inhibits cell ap …
Gilteritinib reverses ABCB1-mediated multidrug resistance: Preclinical in vitro and animal investigations.
Zhang M, She ML, Chen J, Zeng XQ, Xiong QQ, Cen YH, Ye JA, Qiu GB, Yang SY, Ren GH. Zhang M, et al. Biomed Pharmacother. 2024 Nov;180:117603. doi: 10.1016/j.biopha.2024.117603. Epub 2024 Oct 30. Biomed Pharmacother. 2024. PMID: 39471652 Free article.
Multi-drug resistance (MDR) poses a significant challenge to cancer treatment. Targeting ATP-binding cassette subfamily B member 1 (ABCB1) is a viable strategy for overcoming MDR. ...At nontoxic levels, gilteritinib significantly increased the susceptibility of cancer
Multi-drug resistance (MDR) poses a significant challenge to cancer treatment. Targeting ATP-binding cassette subfamily B member 1 (A …
Clinical Pharmacology of Asciminib: A Review.
Hoch M, Huth F, Manley PW, Loisios-Konstantinidis I, Combes FP, Li YF, Fu Y, Sy SKB, Obourn V, Chakraborty A, Hourcade-Potelleret F. Hoch M, et al. Clin Pharmacokinet. 2024 Nov;63(11):1513-1528. doi: 10.1007/s40262-024-01428-6. Epub 2024 Oct 29. Clin Pharmacokinet. 2024. PMID: 39467980 Free PMC article. Review.
This review focuses on the pharmacokinetic (PK) and pharmacodynamic data of asciminib, which is approved at a total daily dose of 80 mg for the treatment of adult patients with chronic myeloid leukemia in chronic phase who are either resistant or intolerant to 2 tyrosine
This review focuses on the pharmacokinetic (PK) and pharmacodynamic data of asciminib, which is approved at a total daily dose of 80 mg for …
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].
de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A. de Azambuja E, et al. ESMO Open. 2024 Nov;9(11):103938. doi: 10.1016/j.esmoop.2024.103938. Epub 2024 Oct 17. ESMO Open. 2024. PMID: 39418883 Free PMC article. Clinical Trial.
BACKGROUND: Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. Here we present the final 10-year analysis of the ALTTO trial. PATIENTS AND METHODS: The ALTTO …
BACKGROUND: Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastat …
Polypharmacological profiling across protein target families and cellular pathways using the multiplexed cell-based assay platform safetyProfiler reveals efficacy, potency and side effects of drugs.
Popović L, Brankatschk B, Palladino G, Rossner MJ, Wehr MC. Popović L, et al. Biomed Pharmacother. 2024 Nov;180:117523. doi: 10.1016/j.biopha.2024.117523. Epub 2024 Oct 14. Biomed Pharmacother. 2024. PMID: 39405910 Free article.
Furthermore, we present data on the selectivity for bazedoxifene, an estrogen receptor antagonist currently undergoing clinical phase 2 trials for breast cancer, on MAPK signaling. Additionally, precise potency data for LY2452473, an androgen receptor antagonist, th …
Furthermore, we present data on the selectivity for bazedoxifene, an estrogen receptor antagonist currently undergoing clinical phase 2 tria …
PPARgamma antagonism as a new tool for preventing or overcoming endocrine resistance in luminal A breast cancers.
Boretto C, Muzio G, Autelli R. Boretto C, et al. Biomed Pharmacother. 2024 Nov;180:117461. doi: 10.1016/j.biopha.2024.117461. Epub 2024 Sep 25. Biomed Pharmacother. 2024. PMID: 39326102 Free article.
PURPOSE: This research investigates the role of PPARgamma in the complex molecular events underlying the acquisition of resistance to tamoxifen (Tam) in luminal A breast cancer (BC) cells. Furthermore, it focuses on evaluating the possibility of repurposing Imatinib …
PURPOSE: This research investigates the role of PPARgamma in the complex molecular events underlying the acquisition of resistance to tamoxi …
First-line endocrine therapy for hormone receptor positive and HER-2 negative metastatic breast cancer: A Bayesian network meta-analysis.
Jiang YC, Yang JJ, Zhang HT, Zhuo R, De La Roche S, Torres-De La Roche LA, De Wilde RL, Dong J. Jiang YC, et al. Oncol Lett. 2024 Aug 28;28(5):513. doi: 10.3892/ol.2024.14646. eCollection 2024 Nov. Oncol Lett. 2024. PMID: 39247493 Free PMC article.
Endocrine therapy has become the fundamental treatment option for hormone receptor-positive (HR(+)) and receptor tyrosine-protein kinase erbB-2-negative (HER2(-)) metastatic breast cancer (mBC). While treatments incorporating cyclin-dependent kinase
Endocrine therapy has become the fundamental treatment option for hormone receptor-positive (HR(+)) and receptor tyrosine-protein …
Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo.
Conlon NT, Roche S, Mahdi AF, Browne A, Breen L, Gaubatz J, Meiller J, O'Neill F, O'Driscoll L, Cremona M, Hennessy BT, Eli LD, Crown J, Collins DM. Conlon NT, et al. Transl Oncol. 2024 Nov;49:102073. doi: 10.1016/j.tranon.2024.102073. Epub 2024 Aug 26. Transl Oncol. 2024. PMID: 39191139 Free PMC article.
BACKGROUND: HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resistance or the emergence of acquired resistance is a persistent clinical problem. ...CONCLUSIONS: This study provides a strong pre-clinical rati …
BACKGROUND: HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resista …
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022.
Freedman RA, Heiling HM, Li T, Trapani D, Tayob N, Smith KL, Davis R, Pereslete AM, DeMeo MK, Cotter C, Chen WY, Parsons HA, Santa-Maria CA, Van Poznak C, Moy B, Brufsky AM, Melisko ME, O'Sullivan CC, Ashai N, Rauf Y, Nangia JR, Burns RT, Savoie J, Wolff AC, Winer EP, Rimawi MF, Krop IE, Lin NU. Freedman RA, et al. Ann Oncol. 2024 Nov;35(11):993-1002. doi: 10.1016/j.annonc.2024.07.245. Epub 2024 Jul 6. Ann Oncol. 2024. PMID: 38977064 Free article. Clinical Trial.
BACKGROUND: Treatment options for human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases (BCBMs) remain limited. We previously reported central nervous system (CNS) activity for neratinib and neratinib-capecitabine. Preclinical data …
BACKGROUND: Treatment options for human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases (BCB …
Kinin Receptors B1 and B2 Mediate Breast Cancer Cell Migration and Invasion by Activating the FAK-Src Axis.
González-Turén F, Lobos-González L, Riquelme-Herrera A, Ibacache A, Meza Ulloa L, Droguett A, Alveal C, Carrillo B, Gutiérrez J, Ehrenfeld P, Cárdenas-Oyarzo A. González-Turén F, et al. Int J Mol Sci. 2024 Oct 31;25(21):11709. doi: 10.3390/ijms252111709. Int J Mol Sci. 2024. PMID: 39519260 Free PMC article.
Kinin receptors B1 and B2 are involved in migration and invasion in gastric, glioma, and cervical cancer cells, among others. However, the role of kinin receptors in breast cancer cells has been poorly studied. ...Moreover, the migration and invasion induced …
Kinin receptors B1 and B2 are involved in migration and invasion in gastric, glioma, and cervical cancer cells, among others. However …
Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies.
Iweala EEJ, Amuji DN, Oluwajembola AM, Ugbogu EA. Iweala EEJ, et al. Curr Res Pharmacol Drug Discov. 2024 Oct 22;7:100204. doi: 10.1016/j.crphar.2024.100204. eCollection 2024. Curr Res Pharmacol Drug Discov. 2024. PMID: 39524211 Free PMC article. Review.
Breast cancer presents a significant challenge due to its heterogeneity and propensity for developing chemoresistance, particularly in the triple-negative subtype. c-Mesenchymal epithelial transition factor (c-Met), a receptor tyrosine kinase, presents
Breast cancer presents a significant challenge due to its heterogeneity and propensity for developing chemoresistance, particu
Management of follicular thyroid carcinoma.
Yamazaki H, Sugino K, Katoh R, Matsuzu K, Kitagawa W, Nagahama M, Saito A, Ito K. Yamazaki H, et al. Eur Thyroid J. 2024 Oct 16;13(5):e240146. doi: 10.1530/ETJ-24-0146. Print 2024 Oct 1. Eur Thyroid J. 2024. PMID: 39419099 Free PMC article. Review.
However, some FTCs become refractory to RAI. Multi-tyrosine kinase inhibitors such as sorafenib and lenvatinib are utilized for treating RAI-refractory FTCs. In addition, given that renin-angiotensin system (RAS) is the most common driver gene for FTC, it is …
However, some FTCs become refractory to RAI. Multi-tyrosine kinase inhibitors such as sorafenib and lenvatinib are util …
Immunotherapy and Tyrosine Kinase Inhibitor as a Bridge to Surgery for Clear Cell Renal Cell Carcinoma Metastases to the Thyroid: A Case Report and Literature Review.
Bränström R, Zedenius J, Shabo I, Lindskog M, Juhlin CC. Bränström R, et al. Case Rep Oncol. 2024 Oct 9;17(1):1124-1130. doi: 10.1159/000541329. eCollection 2024 Jan-Dec. Case Rep Oncol. 2024. PMID: 39474531 Free PMC article.
INTRODUCTION: Clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer in adults, presents significant challenges owing to its resistance to conventional therapies. ...Recent shifts in treatment paradigms, especially with the integration of molecular …
INTRODUCTION: Clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer in adults, presents significant challeng …
Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer.
Zhang D, Taylor A, Zhao JJ, Endres CJ, Topletz-Erickson A. Zhang D, et al. Clin Pharmacokinet. 2024 Oct;63(10):1477-1487. doi: 10.1007/s40262-024-01412-0. Epub 2024 Oct 5. Clin Pharmacokinet. 2024. PMID: 39368039 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVE: Tucatinib is a highly selective, oral, reversible, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor. Tucatinib is approved at a 300-mg twice-daily dose in adults in combination with trastuzumab and capecita …
BACKGROUND AND OBJECTIVE: Tucatinib is a highly selective, oral, reversible, human epidermal growth factor receptor 2 (HER2)-specific tyr
Developing combination therapies with biologics in triple-negative breast cancer.
Gaudio G, Martino E, Pellizzari G, Cavallone M, Castellano G, Omar A, Katselashvili L, Trapani D, Curigliano G. Gaudio G, et al. Expert Opin Biol Ther. 2024 Oct;24(10):1075-1094. doi: 10.1080/14712598.2024.2408756. Epub 2024 Oct 3. Expert Opin Biol Ther. 2024. PMID: 39360776 Free article. Review.
INTRODUCTION: Novel compounds have entered the triple-negative breast cancer (TNBC) treatment algorithm, namely immune checkpoints inhibitors (ICIs), PARP inhibitors and antibody-drug conjugates (ADCs). ...AREAS COVERED: The development of new drugs oc …
INTRODUCTION: Novel compounds have entered the triple-negative breast cancer (TNBC) treatment algorithm, namely immune checkpo …
FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells.
Mezquita B, Reyes-Farias M, Pons M. Mezquita B, et al. Biomed Pharmacother. 2024 Oct;179:117325. doi: 10.1016/j.biopha.2024.117325. Epub 2024 Sep 2. Biomed Pharmacother. 2024. PMID: 39226729 Free article.
Here we show that these compounds inhibit the proliferation, invasion, and colony formation of triple-negative MDA-MB-231 breast cancer cells, SRC-transduced SW620 colon cancer cells and SRC- transduced NIH3T3 fibroblasts. DCV also inhibits the expression of …
Here we show that these compounds inhibit the proliferation, invasion, and colony formation of triple-negative MDA-MB-231 breast c
3,3'4-trimethoxy-4'-rutinosylellagic acid and its acetylated derivative: Antioxidant activity and antiproliferative effects on breast cancer cells and molecular docking study.
Feunaing RT, Tamfu AN, Gbaweng AJY, Djoko CLT, Ntchapda F, Henoumont C, Laurent S, Talla E, Anouar EH, Zingue S, Dinica RM. Feunaing RT, et al. Biomed Pharmacother. 2024 Oct;179:117370. doi: 10.1016/j.biopha.2024.117370. Epub 2024 Aug 28. Biomed Pharmacother. 2024. PMID: 39208664 Free article.

Both compounds had good antioxidant effects with TR2 being more active than TR22. Both compounds inhibited growth of breast carcinoma cells when compared to the untreated controls after 72 h. Compound TR22 significantly (p < 0.001) inhibited proliferation of both MCF-7

Both compounds had good antioxidant effects with TR2 being more active than TR22. Both compounds inhibited growth of breast carcinoma …
Ferroptosis - a potential feature underlying neratinib-induced colonic epithelial injury.
Nguyen TPM, Woods SL, Secombe KR, Tang S, Elz AS, Ayton S, Finnie J, Nagpal A, Pouliot N, Bowen JM. Nguyen TPM, et al. Cancer Chemother Pharmacol. 2024 Oct;94(4):493-505. doi: 10.1007/s00280-024-04699-9. Epub 2024 Jul 13. Cancer Chemother Pharmacol. 2024. PMID: 39002022 Free PMC article.
PURPOSE: Neratinib, a small-molecule tyrosine kinase inhibitor (TKI) that irreversibly binds to human epidermal growth factor receptors 1, 2 and 4 (HER1/2/4), is an approved extended adjuvant therapy for patients with HER2-amplified or -overexpressed (HER2-positive) …
PURPOSE: Neratinib, a small-molecule tyrosine kinase inhibitor (TKI) that irreversibly binds to human epidermal growth factor …
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.
Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, Anurag M, Holt MV, Gou X, Pilcher JB, Goetz MP, Northfelt DW, Hilsenbeck SG, Marshall CG, Hyer ML, Papp R, Yin SY, De Angelis C, Schiff R, Fuqua SAW, Ma CX, Foulds CE, Ellis MJ. Chen A, et al. Mol Cancer Ther. 2024 Oct 1;23(10):1494-1510. doi: 10.1158/1535-7163.MCT-23-0564. Mol Cancer Ther. 2024. PMID: 38781103 Free PMC article.
Endocrine therapies (ET) with cyclin-dependent kinase 4/6 (CDK4/6) inhibition are the standard treatment for estrogen receptor-alpha-positive (ER+) breast cancer, however drug resistance is common. In this study, proteogenomic analyses of patient-derived xeno …
Endocrine therapies (ET) with cyclin-dependent kinase 4/6 (CDK4/6) inhibition are the standard treatment for estrogen receptor-alpha- …
Breast Cancer Brain Metastasis: A Comprehensive Review.
Raghavendra AS, Ibrahim NK. Raghavendra AS, et al. JCO Oncol Pract. 2024 Oct;20(10):1348-1359. doi: 10.1200/OP.23.00794. Epub 2024 May 15. JCO Oncol Pract. 2024. PMID: 38748968 Free PMC article. Review.
The mechanisms underlying breast cancer brain metastasis (BCBM) development are complex, and its clinical presentation varies depending on the number, location, and size of brain metastases. ...Novel agents, such as human epidermal growth factor receptor 2 (HER2)-ta …
The mechanisms underlying breast cancer brain metastasis (BCBM) development are complex, and its clinical presentation varies …
A SRC-slug-TGFbeta2 signaling axis drives poor outcomes in triple-negative breast cancers.
Angel CZ, Beattie S, Hanif EAM, Ryan MP, Guerra Liberal FDC, Zhang SD, Monteith S, Buckley NE, Parker E, Haynes S, McIntyre AJ, Haddock P, Sharifova M, Branco CM, Mullan PB. Angel CZ, et al. Cell Commun Signal. 2024 Sep 26;22(1):454. doi: 10.1186/s12964-024-01793-6. Cell Commun Signal. 2024. PMID: 39327614 Free PMC article.
BACKGROUND: Treatment options for the Triple-Negative Breast Cancer (TNBC) subtype remain limited and the outcome for patients with advanced TNBC is very poor. ...In our study, we focused on a particular subtype of aggressive breast cancer called Tripl …
BACKGROUND: Treatment options for the Triple-Negative Breast Cancer (TNBC) subtype remain limited and the outcome for patients …
High WEE1 expression is independently linked to poor survival in multiple myeloma.
Simhal AK, Firestone R, Oh JH, Avutu V, Norton L, Hultcrantz M, Usmani SZ, Maclachlan KH, Deasy JO. Simhal AK, et al. bioRxiv [Preprint]. 2024 Sep 24:2024.09.20.613788. doi: 10.1101/2024.09.20.613788. bioRxiv. 2024. PMID: 39386721 Free PMC article. Preprint.
We therefore analyzed the MMRF CoMMpass dataset (N=659) and identified a high-risk group (top tertile) and a low-risk group ( bottom tertile) based on WEE1 expression sorted in descending order. The tyrosine kinase WEE1 is a critical cell cycle regulator during the …
We therefore analyzed the MMRF CoMMpass dataset (N=659) and identified a high-risk group (top tertile) and a low-risk group ( bottom tertile …
HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future.
Xu L, Xie Y, Gou Q, Cai R, Bao R, Huang Y, Tang R. Xu L, et al. Front Pharmacol. 2024 Sep 16;15:1446414. doi: 10.3389/fphar.2024.1446414. eCollection 2024. Front Pharmacol. 2024. PMID: 39351085 Free PMC article. Review.
Breast cancer (BC) has the second highest incidence among cancers and is the leading cause of death among women worldwide. ...The development of HER2-targeted drugs, including monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs) and a
Breast cancer (BC) has the second highest incidence among cancers and is the leading cause of death among women worldwide. ...
Receptor tyrosine kinases in breast cancer treatment: unraveling the potential.
Qi Y, Deng SM, Wang KS. Qi Y, et al. Am J Cancer Res. 2024 Sep 15;14(9):4172-4196. doi: 10.62347/KIVS3169. eCollection 2024. Am J Cancer Res. 2024. PMID: 39417188 Free PMC article. Review.
Receptor tyrosine kinases (RTKs), a class of critical receptors, are involved in the initiation and progression of breast cancer. ...The critical role of RTKs makes them suitable targets for breast cancer treatment. Targeted therapies against RT …
Receptor tyrosine kinases (RTKs), a class of critical receptors, are involved in the initiation and progression of breast c
Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases.
Wang L, Lin Y, Yao Z, Babu N, Lin W, Chen C, Du L, Cai S, Pan Y, Xiong X, Ye Q, Ren H, Zhang D, Chen Y, Yeung SJ, Bremer E, Zhang H. Wang L, et al. Drug Resist Updat. 2024 Sep;76:101118. doi: 10.1016/j.drup.2024.101118. Epub 2024 Jul 14. Drug Resist Updat. 2024. PMID: 39094301 Free article.
AIMS: Resistance to targeted therapy is one of the critical obstacles in cancer management. Resistance to trastuzumab frequently develops in the treatment for HER2(+) cancers. ...METHODS: Four public datasets were used to screen PTP candidates in relation to trastuzumab re …
AIMS: Resistance to targeted therapy is one of the critical obstacles in cancer management. Resistance to trastuzumab frequently deve …
Interactions of bosutinib with drug transporters: In vitro and In vivo inhibition of organic cation transporter 2, multidrug and toxin extrusion protein 1, and breast cancer resistance protein by bosutinib.
Kang MJ, Kim MJ, Seol Y, Chang JE, Lee KR, Chae YJ. Kang MJ, et al. Biomed Pharmacother. 2024 Sep;178:117114. doi: 10.1016/j.biopha.2024.117114. Epub 2024 Jul 24. Biomed Pharmacother. 2024. PMID: 39053425 Free article.
Bosutinib showed moderate or strong inhibitory effects on organic cation transporter 2, multidrug and toxin extrusion protein 1, and breast cancer resistance protein with IC(50) values of 0.0894, 0.598, and 10.8 M, respectively. ...Bosutinib increased systemic expos …
Bosutinib showed moderate or strong inhibitory effects on organic cation transporter 2, multidrug and toxin extrusion protein 1, and brea
Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy.
Kennedy AS, Brown DB, Fakih M, Jeyarajah R, Jones S, Liu D, Pinato DJ, Sangro B, Sharma NK, Sze DY, Van Cutsem E, Wasan HS. Kennedy AS, et al. J Vasc Interv Radiol. 2024 Sep;35(9):1253-1267.e1. doi: 10.1016/j.jvir.2024.06.006. Epub 2024 Jun 15. J Vasc Interv Radiol. 2024. PMID: 38885899 Free article.
Modified Delphi method was used to develop consensus on statements through online anonymous surveys of the 12 panel members representing the fields of interventional radiology, medical oncology, surgical oncology, hepatology, and pharmacy, focusing on hepatocellular carcinoma (HC …
Modified Delphi method was used to develop consensus on statements through online anonymous surveys of the 12 panel members representing the …
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, Hirai S, Ishida M, Kawachi H, Sawada R, Tachibana Y, Osoegawa A, Horinaka M, Sakai T, Yasuhiro T, Kozaki R, Yano S, Takayama K. Nakamura R, et al. Cancer Lett. 2024 Aug 28;598:217124. doi: 10.1016/j.canlet.2024.217124. Epub 2024 Jul 24. Cancer Lett. 2024. PMID: 39059573 Free article.
We previously reported that combined therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and AXL inhibitor ONO-7475 is effective in preventing the survival of drug-tolerant cells in high-AXL-expressing EGFR-mutated non-smal …
We previously reported that combined therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimer …
Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review.
Geng W, Thomas H, Chen Z, Yan Z, Zhang P, Zhang M, Huang W, Ren X, Wang Z, Ding K, Zhang J. Geng W, et al. Eur J Pharmacol. 2024 Aug 15;977:176725. doi: 10.1016/j.ejphar.2024.176725. Epub 2024 Jun 6. Eur J Pharmacol. 2024. PMID: 38851563 Free article. Review.
Among the RTK family members, Human epidermal growth factor receptor 2 (HER2) and HER3 are particularly relevant to breast cancer. The review delves into the complexities of receptor tyrosine kinase interactions, resistance mechanisms, and the potentia …
Among the RTK family members, Human epidermal growth factor receptor 2 (HER2) and HER3 are particularly relevant to breast cancer
Novel humanized monoclonal antibodies against ROR1 for cancer therapy.
Wei R, Liao X, Li J, Mu X, Ming Y, Peng Y. Wei R, et al. Mol Cancer. 2024 Aug 13;23(1):165. doi: 10.1186/s12943-024-02075-y. Mol Cancer. 2024. PMID: 39138527 Free PMC article.
RESULTS: ROR1 exhibited dramatically higher expression in lung adenocarcinoma, liver cancer and breast cancer, and targeting ROR1 by short-hairpin RNAs significantly inhibited proliferation and migration of cancer cells. ...Moreover, these two antibodi …
RESULTS: ROR1 exhibited dramatically higher expression in lung adenocarcinoma, liver cancer and breast cancer, and targ …
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination.
Zanini E, Forster-Gross N, Bachmann F, Brüngger A, McSheehy P, Litherland K, Burger K, Groner AC, Roceri M, Bury L, Stieger M, Willemsen-Seegers N, de Man J, Vu-Pham D, van Riel HWE, Zaman GJR, Buijsman RC, Kellenberger L, Lane HA. Zanini E, et al. Front Oncol. 2024 Aug 9;14:1447807. doi: 10.3389/fonc.2024.1447807. eCollection 2024. Front Oncol. 2024. PMID: 39184047 Free PMC article.
BACKGROUND: Threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) are common essential kinases that collaborate in activating the spindle assembly checkpoint (SAC) at the kinetochore, ensuring appropriate chromosome alignment and segregation prior to …
BACKGROUND: Threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) are common essential kinases that collaborate …
Therapeutic Senolysis of Axitinib-Induced Senescent Human Lung Cancer Cells.
Kotani H, Han W, Iida Y, Tanino R, Katakawa K, Okimoto T, Tsubata Y, Isobe T, Harada M. Kotani H, et al. Cancers (Basel). 2024 Aug 7;16(16):2782. doi: 10.3390/cancers16162782. Cancers (Basel). 2024. PMID: 39199555 Free PMC article.
BACKGROUND: Tyrosine kinase inhibitors (TKIs) inhibit receptor-mediated signals in cells. Axitinib is a TKI with high specificity for vascular endothelial growth factor receptors (VEGFRs). AIM: We determined whether axitinib could induce senescence in human …
BACKGROUND: Tyrosine kinase inhibitors (TKIs) inhibit receptor-mediated signals in cells. Axitinib is a TKI with high s …
Design, synthesis, and antiproliferative screening of new quinoline derivatives bearing a cis-vinyl triamide motif as apoptosis activators and EGFR-TK inhibitors.
Abd El-Lateef HM, Gaafar A, Alqahtani AS, Al-Mutairi AA, Alshaya DS, Elsaid FG, Fayad E, Farouk NA. Abd El-Lateef HM, et al. RSC Adv. 2024 Aug 7;14(34):24781-24790. doi: 10.1039/d4ra04915b. eCollection 2024 Aug 5. RSC Adv. 2024. PMID: 39114435 Free PMC article.
In this work, a congeneric set of quinoline-tethered cis-vinyl triamide hybrids was prepared and evaluated as EGFR tyrosine kinase inhibitors for the management of breast cancer. All of the prepared hybrids were evaluated for their antiprolifera …
In this work, a congeneric set of quinoline-tethered cis-vinyl triamide hybrids was prepared and evaluated as EGFR tyrosine kinase
Enhanced anti-tumor effects by combination of tucatinib and radiation in HER2-overexpressing human cancer cell lines.
Amrell L, Bär E, Glasow A, Kortmann RD, Seidel C, Patties I. Amrell L, et al. Cancer Cell Int. 2024 Aug 6;24(1):277. doi: 10.1186/s12935-024-03458-3. Cancer Cell Int. 2024. PMID: 39107782 Free PMC article.
BACKGROUND: Tucatinib (TUC), a HER2-directed tyrosine kinase inhibitor, is the first targeted drug demonstrating intracranial efficacy and significantly prolonged survival in metastatic HER2-positive breast cancer (BC) patients with brain metastases. . …
BACKGROUND: Tucatinib (TUC), a HER2-directed tyrosine kinase inhibitor, is the first targeted drug demonstrating intracranial …
Angiogenesis in breast cancer: insights and innovations.
Elayat G, Selim A. Elayat G, et al. Clin Exp Med. 2024 Aug 6;24(1):178. doi: 10.1007/s10238-024-01446-5. Clin Exp Med. 2024. PMID: 39105831 Free PMC article. Review.
This review explores the pivotal role of angiogenesis in breast cancer progression and treatment. It covers biomarkers, imaging techniques, therapeutic approaches, resistance mechanisms, and clinical implications. ...Therapeutic strategies targeting VEGF, tyrosin
This review explores the pivotal role of angiogenesis in breast cancer progression and treatment. It covers biomarkers, imagin …
Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer.
Romero-Pérez I, Díaz-Rodríguez E, Sánchez-Díaz L, Montero JC, Pandiella A. Romero-Pérez I, et al. Oncogenesis. 2024 Aug 4;13(1):30. doi: 10.1038/s41389-024-00531-4. Oncogenesis. 2024. PMID: 39097594 Free PMC article.
Neratinib is a tyrosine kinase inhibitor that is used for the therapy of patients with HER2+ breast tumors. ...Together, these results uncover a role of PADI3 in the regulation of sensitivity to neratinib in breast cancer cells overexpressing HE …
Neratinib is a tyrosine kinase inhibitor that is used for the therapy of patients with HER2+ breast tumors. ...Together …
New Oncologic Drugs from 2008 to 2023-Differences in Approval and Access between the United States, Europe and Brazil.
Barreto RB, Izidoro AM, Miranda MHF. Barreto RB, et al. Curr Oncol. 2024 Aug 2;31(8):4443-4454. doi: 10.3390/curroncol31080332. Curr Oncol. 2024. PMID: 39195315 Free PMC article.
RESULTS: In total, 104 new oncologic drugs for the treatment of solid tumors were approved by the three agencies: 98 by the FDA, 90 by the EMA, and 68 by ANVISA. The cancer types with the highest number of first indications were lung cancer (n = 24), breast
RESULTS: In total, 104 new oncologic drugs for the treatment of solid tumors were approved by the three agencies: 98 by the FDA, 90 by the E …
REThinking the role of the RET oncogene in breast cancer.
Di Grazia G, Conti C, Nucera S, Motta G, Martorana F, Stella S, Massimino M, Giuliano M, Vigneri P. Di Grazia G, et al. Front Oncol. 2024 Aug 1;14:1427228. doi: 10.3389/fonc.2024.1427228. eCollection 2024. Front Oncol. 2024. PMID: 39211557 Free PMC article. Review.
Nevertheless, the ways RET alterations could impact the prognosis of breast cancer and its response to treatment remain only partially elucidated. Several inhibitors of RET kinase have been developed thus far, with various degrees of selectivity toward …
Nevertheless, the ways RET alterations could impact the prognosis of breast cancer and its response to treatment remain only p …
Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib-induced diarrhea in HER2-positive breast cancer-A pilot study.
Bowen J, Braga S, Zotto VD, Finnie J, DiPrimeo D, Cooke B, Bischof GF, Wong A, Di Palma JA. Bowen J, et al. Physiol Rep. 2024 Aug;12(16):e70008. doi: 10.14814/phy2.70008. Physiol Rep. 2024. PMID: 39187401 Free PMC article. Clinical Trial.
The irreversible pan-HER tyrosine kinase inhibitor neratinib is approved for patients with HER2-positive, early-stage and metastatic breast cancer (BC). ...
The irreversible pan-HER tyrosine kinase inhibitor neratinib is approved for patients with HER2-positive, early-stage and meta …
Energy-stress-mediated activation of AMPK sensitizes MPS1 kinase inhibition in triple-negative breast cancer.
Lim JS, Kim E, Song JS, Ahn S. Lim JS, et al. Oncol Rep. 2024 Aug;52(2):101. doi: 10.3892/or.2024.8760. Epub 2024 Jun 21. Oncol Rep. 2024. PMID: 38904203 Free PMC article.
Monopolar spindle 1 kinase (Mps1, also known as TTK protein kinase) inhibitors exert marked anticancer effects against triple-negative breast cancer (TNBC) by causing genomic instability and cell death. As aneuploid cells are vulnerable to compo …
Monopolar spindle 1 kinase (Mps1, also known as TTK protein kinase) inhibitors exert marked anticancer effects against …
"Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper".
Conte P, Ciruelos E, Curigliano G, De Laurentiis M, Del Mastro L, Gennari A, Llombart A, Martìn M, Poggio F, Prat A, Puglisi F, Saura C. Conte P, et al. Breast. 2024 Aug;76:103742. doi: 10.1016/j.breast.2024.103742. Epub 2024 May 16. Breast. 2024. PMID: 38772190 Free PMC article.
INTRODUCTION: Advancements in monoclonal antibodies, tyrosine kinase inhibitors, and antibody drug conjugates (ADCs) have notably enhanced outcomes for metastatic HER2-positive breast cancer patients. ...METHODS: To refine HER2-positive metastat …
INTRODUCTION: Advancements in monoclonal antibodies, tyrosine kinase inhibitors, and antibody drug conjugates (ADCs) ha …
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer.
Cai A, Chen Y, Wang LS, Cusick JK, Shi Y. Cai A, et al. Cancers (Basel). 2024 Jul 24;16(15):2635. doi: 10.3390/cancers16152635. Cancers (Basel). 2024. PMID: 39123362 Free PMC article. Review.
At the genetic level, HER2 is encoded by the ERBB2 gene (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2), which is frequently mutated or amplified in cancers, thus spurring extensive research into HER2 modulation and inhibition as viable anti-cancer strate …
At the genetic level, HER2 is encoded by the ERBB2 gene (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2), which is frequent …
Case Report of Complete Response to Olaparib in a Patient with Breast Cancer Brain Metastases.
Asazuma K, Shimomura A, Kawamura Y, Taniyama T, Shimizu C. Asazuma K, et al. Case Rep Oncol. 2024 Jul 20;17(1):773-778. doi: 10.1159/000540257. eCollection 2024 Jan-Dec. Case Rep Oncol. 2024. PMID: 39144243 Free PMC article.
INTRODUCTION: Breast cancer is the second most common cause of central nervous system (CNS) metastases. ...Although treatment options for ErbB2 Receptor Tyrosine Kinase 2 (ERBB2)-positive breast cancer brain metastasis (BCBM) have been re …
INTRODUCTION: Breast cancer is the second most common cause of central nervous system (CNS) metastases. ...Although treatment …
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka.
Gunasekara ADM, Youngkong S, Anothaisintawee T, Dejthevaporn T, Fernandopulle R, Chaikledkaew U. Gunasekara ADM, et al. Sci Rep. 2024 Jul 20;14(1):16736. doi: 10.1038/s41598-024-67598-2. Sci Rep. 2024. PMID: 39033229 Free PMC article.
This study aimed to assess the cost-utility and budget impact of dual to single HER2 targeted neoadjuvant therapy for HER2-positive breast cancer in Sri Lanka. A five-health state Markov model with lifetime horizon was used to assess the cost-utility of neoadjuvant …
This study aimed to assess the cost-utility and budget impact of dual to single HER2 targeted neoadjuvant therapy for HER2-positive breas
Trackins (Trk-Targeting Drugs): A Novel Therapy for Different Diseases.
Chaldakov GN, Aloe L, Yanev SG, Fiore M, Tonchev AB, Vinciguerra M, Evtimov NT, Ghenev P, Dikranian K. Chaldakov GN, et al. Pharmaceuticals (Basel). 2024 Jul 19;17(7):961. doi: 10.3390/ph17070961. Pharmaceuticals (Basel). 2024. PMID: 39065809 Free PMC article. Review.
We herein discuss neurotrophins with pathogenic or metabotrophic abilities, particularly brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), pro-NGF, neurotrophin-3 (NT-3), and their receptor Trk (tyrosine receptor kinase; pronounced "track"). Indee …
We herein discuss neurotrophins with pathogenic or metabotrophic abilities, particularly brain-derived neurotrophic factor (BDNF), nerve gro …
Cheminformatics-based identification of phosphorylated RET tyrosine kinase inhibitors for human cancer.
Talukder MEK, Aktaruzzaman M, Siddiquee NH, Islam S, Wani TA, Alkahtani HM, Zargar S, Raihan MO, Rahman MM, Pokhrel S, Ahammad F. Talukder MEK, et al. Front Chem. 2024 Jul 17;12:1407331. doi: 10.3389/fchem.2024.1407331. eCollection 2024. Front Chem. 2024. PMID: 39086985 Free PMC article.
BACKGROUND: Rearranged during transfection (RET), an oncogenic protein, is associated with various cancers, including non-small-cell lung cancer (NSCLC), papillary thyroid cancer (PTC), pancreatic cancer, medullary thyroid cancer (MTC), breast
BACKGROUND: Rearranged during transfection (RET), an oncogenic protein, is associated with various cancers, including non-small-cell lung …
HER3 receptor and its role in the therapeutic management of metastatic breast cancer.
Zhu M, Yu M, Meng Y, Yang J, Wang X, Li L, Liang Y, Kong F. Zhu M, et al. J Transl Med. 2024 Jul 17;22(1):665. doi: 10.1186/s12967-024-05445-8. J Transl Med. 2024. PMID: 39020378 Free PMC article. Review.
Metastatic breast cancer (mBC) poses a significant threat to women's health and is a major cause of malignant neoplasms in women. Human epidermal growth factor receptor (HER)3, an integral member of the ErbB/HER receptor tyrosine kinase family, …
Metastatic breast cancer (mBC) poses a significant threat to women's health and is a major cause of malignant neoplasms
Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer: mechanisms and role in endocrine resistance.
Marin A, Morales F, Walbaum B. Marin A, et al. Front Oncol. 2024 Jul 8;14:1406951. doi: 10.3389/fonc.2024.1406951. eCollection 2024. Front Oncol. 2024. PMID: 39040443 Free PMC article. Review.
Current clinical trials, including those evaluating FGFR inhibitors like erdafitinib, lucitanib, and dovitinib, have demonstrated mixed outcomes, underscoring the complexity of FGFR signaling in breast cancer. ...In conclusion, targeting FGFR signaling in ER+ …
Current clinical trials, including those evaluating FGFR inhibitors like erdafitinib, lucitanib, and dovitinib, have demonstrated mix …
Synthesis and Antiproliferative Effect of New Alkyne-Tethered Vindoline Hybrids Containing Pharmacophoric Fragments.
Ferenczi E, Keglevich P, Tayeb BA, Minorics R, Papp D, Schlosser G, Zupkó I, Hazai L, Csámpai A. Ferenczi E, et al. Int J Mol Sci. 2024 Jul 6;25(13):7428. doi: 10.3390/ijms25137428. Int J Mol Sci. 2024. PMID: 39000534 Free PMC article.
The novel hybrids with additional pharmacophoric fragments of well-documented anticancer agents, including FDA-approved tyrosine-kinase inhibitors (imatinib and erlotinib) or ferrocene or chalcone units, were evaluated for their antiproliferative activity on …
The novel hybrids with additional pharmacophoric fragments of well-documented anticancer agents, including FDA-approved tyrosine-k
New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?
Scandurra G, Lombardo V, Scibilia G, Sambataro D, Gebbia V, Scollo P, Pecorino B, Valerio MR. Scandurra G, et al. Cancers (Basel). 2024 Jul 5;16(13):2466. doi: 10.3390/cancers16132466. Cancers (Basel). 2024. PMID: 39001528 Free PMC article. Review.
Brain metastases (BM) pose a significant challenge in the management of HER2+ breast cancer since almost 50% of patients with HER2+ breast cancer develop brain tumors. ...While radiotherapy is still fundamental in local therapy, its use is associated w …
Brain metastases (BM) pose a significant challenge in the management of HER2+ breast cancer since almost 50% of patients with …
Long-term survival in a patient with metastatic parathyroid carcinoma harboring an EGFR sensitizing mutation: a case report.
Ying Y, Li H, Xia W, Cheng T, Li H, Fu Q, Ai T, Yang Y, Zhang N, Li X, Ao Q, Du Y, Yang Z. Ying Y, et al. J Int Med Res. 2024 Jul;52(7):3000605241259669. doi: 10.1177/03000605241259669. J Int Med Res. 2024. PMID: 39053452 Free PMC article.
T2573G) mutation, which may sensitize the EGFR-tyrosine kinase inhibitor response, and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) p.E545KV (c. ...After multidisciplinary treatment discussions, the patient was treated with …
T2573G) mutation, which may sensitize the EGFR-tyrosine kinase inhibitor response, and phosphatidylinositol-4,5-bisphosphate 3 …
Tyrosine kinase inhibitors in HER2-positive metastatic breast cancer with trastuzumab emtansine resistance: insights from a multicenter retrospective real-world study.
Sun C, Hua Y, Jin N, Wang X, Huang J, Wu X, Zeng T, Yan X, Yang F, Liang Y, Huang X, Li W, Yin Y. Sun C, et al. MedComm (2020). 2024 Jun 19;5(7):e624. doi: 10.1002/mco2.624. eCollection 2024 Jul. MedComm (2020). 2024. PMID: 38903538 Free PMC article.
The use of trastuzumab emtansine (T-DM1) has revealed significant efficacy in HER2-positive metastatic breast cancer (MBC). However, optimal therapeutic strategies following T-DM1 failure remain a subject of debate in clinical practice. In this multicenter, retrospe …
The use of trastuzumab emtansine (T-DM1) has revealed significant efficacy in HER2-positive metastatic breast cancer (MBC). Ho …
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer.
Momeny M, Tienhaara M, Sharma M, Chakroborty D, Varjus R, Takala I, Merisaari J, Padzik A, Vogt A, Paatero I, Elenius K, Laajala TD, Kurppa KJ, Westermarck J. Momeny M, et al. EMBO Mol Med. 2024 Jul;16(7):1603-1629. doi: 10.1038/s44321-024-00088-0. Epub 2024 Jun 17. EMBO Mol Med. 2024. PMID: 38886591 Free PMC article.
Despite clinical benefits of tyrosine kinase inhibitors (TKIs) in cancer, most tumors can reactivate proliferation under TKI therapy. Here we present transcriptional profiling of HER2+ breast cancer cells transitioning from dormant drug t …
Despite clinical benefits of tyrosine kinase inhibitors (TKIs) in cancer, most tumors can reactivate proliferati …
Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers.
Somme LB, Chouaid C, Moinard-Butot F, Barbe-Richaud JB, Greillier L, Schott R. Somme LB, et al. BioDrugs. 2024 Jul;38(4):487-497. doi: 10.1007/s40259-024-00660-7. Epub 2024 May 20. BioDrugs. 2024. PMID: 38767823 Free PMC article. Review.
In patients with EGFR-mutated or ALK-rearranged NSCLC, tyrosine kinase inhibitors (TKIs) are recommended. However, although the prognosis of patients with metastatic NSCLC differs between such with and without alterations in oncogenic drivers, most patients e …
In patients with EGFR-mutated or ALK-rearranged NSCLC, tyrosine kinase inhibitors (TKIs) are recommended. However, alth …
Targeted blocking of EGFR and GLUT1 by compound H reveals a new strategy for treatment of triple-negative breast cancer and nasopharyngeal carcinoma.
Wang C, Li Z, Zhai H, Shen X, Li F, Zhang Q, Li D, Hou H. Wang C, et al. Eur J Pharm Sci. 2024 Jul 1;198:106789. doi: 10.1016/j.ejps.2024.106789. Epub 2024 May 4. Eur J Pharm Sci. 2024. PMID: 38710335 Free article.
BACKGROUND: Cytoplasmic epidermal growth factor receptor (EGFR) is overexpressed in both nasopharyngeal carcinoma (NPC) and triple-negative breast cancer (TNBC), while clinical outcome and prognosis vary greatly among patients treated with gefitinib, and all patient …
BACKGROUND: Cytoplasmic epidermal growth factor receptor (EGFR) is overexpressed in both nasopharyngeal carcinoma (NPC) and triple-negative …
Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic EGFR-mutated non-small cell lung cancer: present and future developments.
Zhao X, Zhang S, Sun X, Lin Y, Capone L, Ko EC, Kann BH, Li Y, Wang X. Zhao X, et al. Transl Lung Cancer Res. 2024 Jun 30;13(6):1383-1395. doi: 10.21037/tlcr-24-414. Epub 2024 Jun 27. Transl Lung Cancer Res. 2024. PMID: 38973945 Free PMC article. Review.
BACKGROUND AND OBJECTIVE: A significant number of individuals diagnosed with non-small cell lung cancer (NSCLC) have distant metastases, and the concept of oligometastatic NSCLC has shown promise in achieving a cure. ...It has also been demonstrated that third-generation …
BACKGROUND AND OBJECTIVE: A significant number of individuals diagnosed with non-small cell lung cancer (NSCLC) have distant metastas …
Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer.
Ferro A, Campora M, Caldara A, De Lisi D, Lorenzi M, Monteverdi S, Mihai R, Bisio A, Dipasquale M, Caffo O, Ciribilli Y. Ferro A, et al. J Clin Med. 2024 Jun 20;13(12):3611. doi: 10.3390/jcm13123611. J Clin Med. 2024. PMID: 38930141 Free PMC article. Review.
Estrogen receptor (ER)-positive breast cancer (BC) is the most common BC subtype. Endocrine therapy (ET) targeting ER signaling still remains the mainstay treatment option for hormone receptor (HR)-positive BC either in the early or in advanced setting, including di …
Estrogen receptor (ER)-positive breast cancer (BC) is the most common BC subtype. Endocrine therapy (ET) targeting ER signalin …
TTK inhibitor OSU13 promotes immunotherapy responses by activating tumor STING.
Bharti V, Kumar A, Wang Y, Roychowdhury N, de Lima Bellan D, Kassaye BB, Watkins R, Capece M, Chung CG, Hilinski G, Vilgelm AE. Bharti V, et al. JCI Insight. 2024 Jun 20;9(15):e177523. doi: 10.1172/jci.insight.177523. JCI Insight. 2024. PMID: 38900577 Free PMC article.
TTK spindle assembly checkpoint kinase is an emerging cancer target. This preclinical study explored the antitumor mechanism of TTK inhibitor OSU13 to define a strategy for clinical development. We observed prominent antitumor activity of OSU13 in melanoma, colon an …
TTK spindle assembly checkpoint kinase is an emerging cancer target. This preclinical study explored the antitumor mechanism o …
Mitotic kinases are emerging therapeutic targets against metastatic breast cancer.
Aquino-Acevedo AN, Orengo-Orengo JA, Cruz-Robles ME, Saavedra HI. Aquino-Acevedo AN, et al. Cell Div. 2024 Jun 17;19(1):21. doi: 10.1186/s13008-024-00125-x. Cell Div. 2024. PMID: 38886738 Free PMC article. Review.
This review aims to outline mitotic kinase inhibitors' roles as potential therapeutic targets and assess their suitability as a stand-alone clinical therapy or in combination with standard treatments for advanced-stage solid tumors, including triple-negative brea
This review aims to outline mitotic kinase inhibitors' roles as potential therapeutic targets and assess their suitability as …
Twenty-five years with HER2 targeted therapy.
Jørgensen JT. Jørgensen JT. Ann Transl Med. 2024 Jun 10;12(3):53. doi: 10.21037/atm-23-153. Epub 2023 Jun 25. Ann Transl Med. 2024. PMID: 38911570 Free PMC article. Review.
The development of trastuzumab is among the most significant cancer drug development projects in the 20th century. Trastuzumab became a gamechanger for the treatment of human epidermal growth receptor 2 (HER2) positive breast cancer, with a significant positi …
The development of trastuzumab is among the most significant cancer drug development projects in the 20th century. Trastuzumab became …
N-phenyl pyrazoline derivative inhibits cell aggressiveness and enhances paclitaxel sensitivity of triple negative breast cancer cells.
Satriyo PB, Mustofa M, Wahyuningsih TD, Damayanti E, Wiraswati HL, Satria D, Bashari MH, Sholikhah EN. Satriyo PB, et al. Sci Rep. 2024 Jun 8;14(1):13200. doi: 10.1038/s41598-024-63778-2. Sci Rep. 2024. PMID: 38851778 Free PMC article.
Many small-molecule kinase inhibitors have been tested in clinical trials to treat TNBC patients. In the previous study, we found that N-phenylpyrazoline small molecule acts as a protein kinase inhibitor in cervical cancer cells. ...Further, the P5 pre …
Many small-molecule kinase inhibitors have been tested in clinical trials to treat TNBC patients. In the previous study, we fo …
STAT3 Pathways Contribute to beta-HCH Interference with Anticancer Tyrosine Kinase Inhibitors.
Fiorini S, Rubini E, Perugini M, Altieri F, Chichiarelli S, Meschiari G, Arrighetti G, Vijgen J, Natali PG, Minacori M, Eufemi M. Fiorini S, et al. Int J Mol Sci. 2024 Jun 4;25(11):6181. doi: 10.3390/ijms25116181. Int J Mol Sci. 2024. PMID: 38892372 Free PMC article.
For this purpose, four cell lines, representative of breast, lung, prostate, and hepatocellular cancers, were treated with beta-HCH, specific tyrosine kinase inhibitors (TKIs), and a STAT3 inhibitor. ...
For this purpose, four cell lines, representative of breast, lung, prostate, and hepatocellular cancers, were treated with beta-HCH, …
IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy.
Moyer CL, Lanier A, Qian J, Coleman D, Hill J, Vuligonda V, Sanders ME, Mazumdar A, Brown PH. Moyer CL, et al. Clin Cancer Res. 2024 Jun 3;30(11):2558-2570. doi: 10.1158/1078-0432.CCR-23-3839. Clin Cancer Res. 2024. PMID: 38578278 Free PMC article.
However, the usefulness of rexinoids in treatment of breast cancer remains unknown. This study examines the efficacy of IRX4204, a highly specific rexinoid, in breast cancer cell lines and preclinical models to identify a biomarker for response and pot …
However, the usefulness of rexinoids in treatment of breast cancer remains unknown. This study examines the efficacy of IRX420 …
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications.
Hunter Hall R, Wright CL, Hughes GK, Peña AM, Ladd C, Gardner B, McIntire R, Ferrell M, Rubenstein J, Tuia J, Haslam A, Prasad V, Vassar M. Hunter Hall R, et al. Clin Ther. 2024 Jun;46(6):e107-e113. doi: 10.1016/j.clinthera.2024.04.006. Epub 2024 Jun 1. Clin Ther. 2024. PMID: 38825553 Free article. Review.
PURPOSE: In 2013, afatinib was approved for non-small-cell lung cancer with subsequent indication expansion. We investigated published afatinib clinical trials to assess risk and benefit profiles for the drug in its approved indication of non-small-cell lung cancer
PURPOSE: In 2013, afatinib was approved for non-small-cell lung cancer with subsequent indication expansion. We investigated publishe …
In silico identification of a novel Cdc2-like kinase 2 (CLK2) inhibitor in triple negative breast cancer.
Huang CC, Hsu CM, Chao MW, Hsu KC, Lin TE, Yen SC, Tu HJ, Pan SL. Huang CC, et al. Protein Sci. 2024 Jun;33(6):e5004. doi: 10.1002/pro.5004. Protein Sci. 2024. PMID: 38723164 Free PMC article.
Dysregulation of RNA splicing processes is intricately linked to tumorigenesis in various cancers, especially breast cancer. Cdc2-like kinase 2 (CLK2), an oncogenic RNA-splicing kinase pivotal in breast cancer, plays a significant role, p …
Dysregulation of RNA splicing processes is intricately linked to tumorigenesis in various cancers, especially breast cancer. C …
Lapatinib combined with doxorubicin causes dose-dependent cardiotoxicity partially through activating the p38MAPK signaling pathway in zebrafish embryos.
Du K, Liu Y, Zhang L, Peng L, Dong W, Jiang Y, Niu M, Sun Y, Wu C, Niu Y, Ding Y. Du K, et al. Biomed Pharmacother. 2024 Jun;175:116637. doi: 10.1016/j.biopha.2024.116637. Epub 2024 Apr 22. Biomed Pharmacother. 2024. PMID: 38653111 Free article.
Because of its enhanced antitumor efficacy, lapatinib (LAP) is commonly used clinically in combination with the anthracycline drug doxorubicin (DOX) to treat metastatic breast cancer. While it is well recognized that this combination chemotherapy can lead to an incr …
Because of its enhanced antitumor efficacy, lapatinib (LAP) is commonly used clinically in combination with the anthracycline drug doxorubic …
Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
Arshad M, Azad A, Chan PYK, Vigneswara V, Feldinger K, Nafi SNM, Laporte-Maguire E, De Santo C, Zuo J, Shaaban AM, Kong A. Arshad M, et al. Br J Cancer. 2024 Jun;130(12):1990-2002. doi: 10.1038/s41416-024-02665-z. Epub 2024 Apr 10. Br J Cancer. 2024. PMID: 38600326 Free PMC article.
METHODS: We investigated the effect of trastuzumab monotherapy and its combination with different HER2 targeting treatments in a panel of breast cancer cell lines and patient-derived organoids (PDOs) using biochemical methods and cell viability assays. ...Adding a d …
METHODS: We investigated the effect of trastuzumab monotherapy and its combination with different HER2 targeting treatments in a panel of …
TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling.
Marugán C, Sanz-Gómez N, Ortigosa B, Monfort-Vengut A, Bertinetti C, Teijo A, González M, Alonso de la Vega A, Lallena MJ, Moreno-Bueno G, de Cárcer G. Marugán C, et al. Mol Oncol. 2024 Jun;18(6):1531-1551. doi: 10.1002/1878-0261.13602. Epub 2024 Feb 15. Mol Oncol. 2024. PMID: 38357786 Free PMC article.
Chromosomal instability (CIN) is a hallmark of cancer aggressiveness, providing genetic plasticity and tumor heterogeneity that allows the tumor to evolve and adapt to stress conditions. ...We find that the overexpression of targeting protein for Xklp2 (TPX2) enhances sens …
Chromosomal instability (CIN) is a hallmark of cancer aggressiveness, providing genetic plasticity and tumor heterogeneity that allow …
Neratinib stimulates senescence of mammary cancer cells by reducing the levels of SIRT1.
Li W, Fu P, Shi P, Hu B, Li H. Li W, et al. Aging (Albany NY). 2024 May 31;16(11):9547-9557. doi: 10.18632/aging.205882. Epub 2024 May 31. Aging (Albany NY). 2024. PMID: 38829772 Free PMC article.
Neratinib, a typical small-molecule, pan-human tyrosine kinase inhibitor (TKI), has been licensed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. ...These findings provide strong preclinical evidence of Nera …
Neratinib, a typical small-molecule, pan-human tyrosine kinase inhibitor (TKI), has been licensed for the treatment of human e …
The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study.
Wang Y, Xu Y, Liu X, Li C, Wang J, Zhang X, Shao B, Zhang J. Wang Y, et al. Gland Surg. 2024 May 30;13(5):654-662. doi: 10.21037/gs-24-81. Epub 2024 May 27. Gland Surg. 2024. PMID: 38845840 Free PMC article.
BACKGROUND: In the past few years, the combination of trastuzumab and paclitaxel has become an important option for human epidermal growth factor receptor-2 (HER2)-positive breast cancer. Small molecule tyrosine kinase inhibitors (TKIs) can brin …
BACKGROUND: In the past few years, the combination of trastuzumab and paclitaxel has become an important option for human epidermal growth f …
Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer.
Li RQ, Yan L, Zhang L, Ma HX, Wang HW, Bu P, Xi YF, Lian J. Li RQ, et al. Sci Rep. 2024 May 29;14(1):12386. doi: 10.1038/s41598-024-62991-3. Sci Rep. 2024. PMID: 38811720 Free PMC article.
Triple-negative breast cancer (TNBC) has high heterogeneity, poor prognosis, and limited treatment success. ...Moreover, mesenchymal-like (MES) tumors displayed enrichment in the receptor tyrosine kinase (RTK)-RAS pathway and potential sensitivity to R …
Triple-negative breast cancer (TNBC) has high heterogeneity, poor prognosis, and limited treatment success. ...Moreover, mesen …
PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer.
Thu YM, Suzawa K, Tomida S, Ochi K, Tsudaka S, Takatsu F, Date K, Matsuda N, Iwata K, Nakata K, Shien K, Yamamoto H, Okazaki M, Sugimoto S, Toyooka S. Thu YM, et al. PLoS One. 2024 May 17;19(5):e0300644. doi: 10.1371/journal.pone.0300644. eCollection 2024. PLoS One. 2024. PMID: 38758826 Free PMC article.
Mechanisms underlying primary and acquired resistance to MET tyrosine kinase inhibitors (TKIs) in managing non-small cell lung cancer remain unclear. ...In H1993-derived resistant cells, MEK inhibitors could be a potential therapeutic strategy f …
Mechanisms underlying primary and acquired resistance to MET tyrosine kinase inhibitors (TKIs) in managing non-small ce …
β-Elemene Reverses Gefitinib Resistance in NSCLC Cells by Inhibiting lncRNA H19-Mediated Autophagy.
Zhang R, Zheng Y, Zhu Q, Gu X, Xiang B, Gu X, Xie T, Sui X. Zhang R, et al. Pharmaceuticals (Basel). 2024 May 14;17(5):626. doi: 10.3390/ph17050626. Pharmaceuticals (Basel). 2024. PMID: 38794196 Free PMC article.
Lung cancer is a leading cause of mortality worldwide, especially among Asian patients with non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. Initially, first-generation EGFR tyrosine kinase inhibitors
Lung cancer is a leading cause of mortality worldwide, especially among Asian patients with non-small cell lung cancer (NSCLC) …
Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies.
Goyette MA, Stevens LE, DePinho CR, Seehawer M, Nishida J, Li Z, Wilde CM, Li R, Qiu X, Pyke AL, Zhao S, Lim K, Tender GS, Northey JJ, Riley NM, Long HW, Bertozzi CR, Weaver VM, Polyak K. Goyette MA, et al. Proc Natl Acad Sci U S A. 2024 May 14;121(20):e2322688121. doi: 10.1073/pnas.2322688121. Epub 2024 May 6. Proc Natl Acad Sci U S A. 2024. PMID: 38709925 Free PMC article.
Brain metastatic breast cancer is particularly lethal largely due to therapeutic resistance. Almost half of the patients with metastatic HER2-positive breast cancer develop brain metastases, representing a major clinical challenge. ...Our results highl …
Brain metastatic breast cancer is particularly lethal largely due to therapeutic resistance. Almost half of the patients with …
Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study.
Hompland I, Boye K, Wiedswang AM, Papakonstantinou A, Røsok B, Joensuu H, Bruland Ø. Hompland I, et al. Acta Oncol. 2024 May 7;63:288-293. doi: 10.2340/1651-226X.2024.39851. Acta Oncol. 2024. PMID: 38712513 Free PMC article. Clinical Trial.
INTRODUCTION: Metastatic gastrointestinal stromal tumour (GIST) is considered incurable, and life-long treatment with tyrosine kinase inhibitors is recommended. We investigated whether selected patients with metastatic GIST may remain in durable remission des …
INTRODUCTION: Metastatic gastrointestinal stromal tumour (GIST) is considered incurable, and life-long treatment with tyrosine kin
Effects of neratinib on angiogenesis and the early stage of the embryo using chicken embryo as a model.
Kheraldine H, Hassan AF, Alhussain H, Al-Thawadi H, Vranic S, Al Moustafa AE. Kheraldine H, et al. Biomol Biomed. 2024 May 2;24(3):575-581. doi: 10.17305/bb.2023.9869. Biomol Biomed. 2024. PMID: 38158791 Free PMC article.
Even though it is essential during normal development, it plays a major role in cancer progression. Neratinib is a pan-human epidermal growth factor receptor (HER) inhibitor that has recently been approved for the treatment of HER2-positive breast cancer. ...
Even though it is essential during normal development, it plays a major role in cancer progression. Neratinib is a pan-human epiderma …
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T, Cottone F, Dunton K, André F, Krop I, Park YH, De Laurentiis M, Miyoshi Y, Armstrong A, Borrego MR, Yerushalmi R, Duhoux FP, Takano T, Lu W, Egorov A, Kim SB. Fehm T, et al. Lancet Oncol. 2024 May;25(5):614-625. doi: 10.1016/S1470-2045(24)00128-1. Lancet Oncol. 2024. PMID: 38697155 Free article. Clinical Trial.
BACKGROUND: In DESTINY-Breast02, patients with HER2-positive unresectable or metastatic breast cancer who received trastuzumab deruxtecan demonstrated superior progression-free and overall survival compared with those receiving treatment of physician's choice. ...PR …
BACKGROUND: In DESTINY-Breast02, patients with HER2-positive unresectable or metastatic breast cancer who received trastuzumab …
Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
Santi I, Vellekoop H, M Versteegh M, A Huygens S, Dinjens WNM, Mölken MR. Santi I, et al. Mol Diagn Ther. 2024 May;28(3):319-328. doi: 10.1007/s40291-024-00704-2. Epub 2024 Apr 14. Mol Diagn Ther. 2024. PMID: 38616205 Free PMC article.
OBJECTIVES: We evaluated the prognostic value of the neurotrophic tyrosine receptor kinase (NTRK) gene fusions by comparing the survival of patients with NTRK+ tumours with patients without NTRK+ tumours. METHODS: We used genomic and clinical registry data from the …
OBJECTIVES: We evaluated the prognostic value of the neurotrophic tyrosine receptor kinase (NTRK) gene fusions by comparing th …
When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?
Fu C, Tong W, Yu L, Miao Y, Wei Q, Yu Z, Chen B, Wei M. Fu C, et al. Pharmacol Res. 2024 May;203:107160. doi: 10.1016/j.phrs.2024.107160. Epub 2024 Mar 26. Pharmacol Res. 2024. PMID: 38547937 Free article. Review.
Commonly used immunostimulatory agents may induce systemic immune reactions, and BTK (Bruton's tyrosine kinase) inhibitors can regulate immunogenicity. Finally, the concept of grafting ADC's therapeutic principles is simple, but the combination of payload, li …
Commonly used immunostimulatory agents may induce systemic immune reactions, and BTK (Bruton's tyrosine kinase) inhibitors
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley KA, Venet D, Rashid NU, Spears PA, Islam MN, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huobe J, Goerlitz D, Hu R, Lucas PC, Swain SM, Sotiriou C, Perou CM, Carey LA. Fernandez-Martinez A, et al. JAMA Oncol. 2024 May 1;10(5):603-611. doi: 10.1001/jamaoncol.2023.7304. JAMA Oncol. 2024. PMID: 38546612 Free PMC article.
IMPORTANCE: Biologic features may affect pathologic complete response (pCR) and event-free survival (EFS) after neoadjuvant chemotherapy plus ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer (EBC). OBJECTIVE: To define the quantitative association betw …
IMPORTANCE: Biologic features may affect pathologic complete response (pCR) and event-free survival (EFS) after neoadjuvant chemotherapy plu …
Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.
Yang L, Bhattacharya A, Peterson D, Li Y, Liu X, Marangoni E, Robila V, Zhang Y. Yang L, et al. Drug Resist Updat. 2024 May;74:101078. doi: 10.1016/j.drup.2024.101078. Epub 2024 Mar 13. Drug Resist Updat. 2024. PMID: 38503142 Free article.
AIMS: Human epidermal growth factor receptor 2 (HER2) is an oncogenic receptor tyrosine kinase amplified in approximately 20% of breast cancer (BC). HER2-targeted therapies are the linchpin of treating HER2-positive BC. ...The findings provide new insi …
AIMS: Human epidermal growth factor receptor 2 (HER2) is an oncogenic receptor tyrosine kinase amplified in approximately 20% …
Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance.
Morgovan C, Dobrea CM, Butuca A, Arseniu AM, Frum A, Rus LL, Chis AA, Juncan AM, Gligor FG, Georgescu C, Ghibu S, Vonica-Tincu AL. Morgovan C, et al. Biomedicines. 2024 Apr 25;12(5):953. doi: 10.3390/biomedicines12050953. Biomedicines. 2024. PMID: 38790915 Free PMC article.
Trastuzumab (T) and tyrosine kinase inhibitors (TKIs) are among the first-line treatments recommended for HER2-positive breast cancer. More recently, antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and trastuzumab emtansin …
Trastuzumab (T) and tyrosine kinase inhibitors (TKIs) are among the first-line treatments recommended for HER2-positive …
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, Srinivasan A, Pogue-Geile KL. Jacobs SA, et al. Breast Cancer Res. 2024 Apr 22;26(1):69. doi: 10.1186/s13058-024-01823-8. Breast Cancer Res. 2024. PMID: 38650031 Free PMC article. Clinical Trial.
BACKGROUND: We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more durable responses. ...
BACKGROUND: We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive …
Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer.
Long L, Fei X, Chen L, Yao L, Lei X. Long L, et al. Front Oncol. 2024 Apr 18;14:1381251. doi: 10.3389/fonc.2024.1381251. eCollection 2024. Front Oncol. 2024. PMID: 38699644 Free PMC article. Review.
Triple-negative breast cancer (TNBC) poses a significant clinical challenge due to its propensity for metastasis and poor prognosis. ...The signal transduction cascade of the JAK2/STAT3 pathway predominantly involves receptor tyrosine kinases, the tyrosine
Triple-negative breast cancer (TNBC) poses a significant clinical challenge due to its propensity for metastasis and poor prog …
DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X, Yao J, Qu C, Luo L, Li B, Zhang Y, Zhu Z, Qiu Y, Hua H. Li X, et al. J Transl Med. 2024 Apr 17;22(1):362. doi: 10.1186/s12967-024-05133-7. J Transl Med. 2024. PMID: 38632563 Free PMC article.
In vitro, DB-1310 exhibited cytotoxicity in numerous HER3 + breast, lung, prostate and colon cancer cell lines. In vivo studies in HER3 + HCC1569 breast cancer, NCI-H441 lung cancer and Colo205 colon cancer xenograft models showed DB-1310 …
In vitro, DB-1310 exhibited cytotoxicity in numerous HER3 + breast, lung, prostate and colon cancer cell lines. In vivo studie …
PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway.
Ma Y, Fang Z, Zhang H, Qi Y, Mao Y, Zheng J. Ma Y, et al. Cell Death Dis. 2024 Apr 12;15(3):199. doi: 10.1038/s41419-024-06502-2. Cell Death Dis. 2024. PMID: 38604999 Free PMC article.
EGFR is highly expressed in most triple-negative breast cancer (TNBC) patients. However, only a small proportion of TNBC patients benefit from EGFR-targeted drugs in clinical trials, and the resistance mechanism is unclear. ...In vitro and in vivo functional assays …
EGFR is highly expressed in most triple-negative breast cancer (TNBC) patients. However, only a small proportion of TNBC patie …
Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer.
Pellecchia S, Franchini M, Viscido G, Arnese R, Gambardella G. Pellecchia S, et al. Genome Med. 2024 Apr 11;16(1):55. doi: 10.1186/s13073-024-01327-2. Genome Med. 2024. PMID: 38605363 Free PMC article.
BACKGROUND: Most primary Triple Negative Breast Cancers (TNBCs) show amplification of the Epidermal Growth Factor Receptor (EGFR) gene, leading to increased protein expression. ...METHODS: To elucidate the underlying mechanisms of this variability, we employ cellular barco …
BACKGROUND: Most primary Triple Negative Breast Cancers (TNBCs) show amplification of the Epidermal Growth Factor Receptor (EGFR) gen …
Selective impact of ALK and MELK inhibition on ERalpha stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer.
Bartoloni S, Pescatori S, Bianchi F, Cipolletti M, Acconcia F. Bartoloni S, et al. Sci Rep. 2024 Apr 8;14(1):8200. doi: 10.1038/s41598-024-59001-x. Sci Rep. 2024. PMID: 38589728 Free PMC article.
Breast cancer (BC) is a leading cause of global cancer-related mortality in women, necessitating accurate tumor classification for timely intervention. Molecular and histological factors, including PAM50 classification, estrogen receptor alpha (ERalpha), b
Breast cancer (BC) is a leading cause of global cancer-related mortality in women, necessitating accurate tumor classif
Chemoinformatics and machine learning techniques to identify novel inhibitors of the lemur tyrosine kinase-3 receptor involved in breast cancer.
Alrumaihi F. Alrumaihi F. Front Mol Biosci. 2024 Apr 4;11:1366763. doi: 10.3389/fmolb.2024.1366763. eCollection 2024. Front Mol Biosci. 2024. PMID: 38638686 Free PMC article.
Breast cancer is still the largest cause of cancer death in women, and around 70% of primary breast cancer patients are estrogen receptor (ER)-positive, which is the most frequent kind of breast cancer. The lemur tyrosine
Breast cancer is still the largest cause of cancer death in women, and around 70% of primary breast cancer
Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE, Leis-Filho AF, Lacerda ZA, de Faria Lainetti P, Amorim RL, Rogatto SR. Fonseca-Alves CE, et al. PLoS One. 2024 Apr 2;19(4):e0297043. doi: 10.1371/journal.pone.0297043. eCollection 2024. PLoS One. 2024. PMID: 38564578 Free PMC article.
The aberrant activation of HER2 has a pivotal role in bone metastasis implantation and progression in several tumor types, including prostate cancer (PC). Trastuzumab and other anti-HER2 therapies, such as lapatinib, have been used in human breast cancer HER2 …
The aberrant activation of HER2 has a pivotal role in bone metastasis implantation and progression in several tumor types, including prostat …
Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial).
Kim HR, Lee SJ, Ahn MS, Kim JE, Kang MJ, Hong JY, Lee J, Kim ST. Kim HR, et al. J Cancer Res Ther. 2024 Apr 1;20(3):972-978. doi: 10.4103/jcrt.jcrt_2698_22. Epub 2023 Apr 4. J Cancer Res Ther. 2024. PMID: 39023605 Free article. Clinical Trial.
The most common tumor type was melanoma (n = 15, 83.3%), followed by ovarian cancer, breast cancer, and metastasis of unknown origin (MUO) (each n = 1, 5.5%). The total number of evaluable patients was 17, of which one patient had a complete response, six pat …
The most common tumor type was melanoma (n = 15, 83.3%), followed by ovarian cancer, breast cancer, and metastasis of u …
Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
Pourjamal N, Yazdi N, Halme A, Joncour VL, Laakkonen P, Saharinen P, Joensuu H, Barok M. Pourjamal N, et al. Clin Exp Metastasis. 2024 Apr;41(2):91-102. doi: 10.1007/s10585-024-10278-2. Epub 2024 Feb 17. Clin Exp Metastasis. 2024. PMID: 38367127 Free PMC article.
Human epidermal growth factor 2 (HER2)-positive breast cancer with lung metastases resistant to targeted agents is a common therapeutic challenge. ...L-JIMT-1 cells were resistant to all five tyrosine kinase inhibitors tested in vitro (afatinib, …
Human epidermal growth factor 2 (HER2)-positive breast cancer with lung metastases resistant to targeted agents is a common th …
Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study.
Jiang K, Hong R, Xia W, Lu Q, Li L, Huang J, Shi Y, Yuan Z, Zheng Q, An X, Xue C, Huang J, Bi X, Chen M, Zhang J, Xu F, Wang S. Jiang K, et al. Cancer Res Treat. 2024 Apr;56(2):513-521. doi: 10.4143/crt.2023.786. Epub 2023 Oct 12. Cancer Res Treat. 2024. PMID: 37846468 Free PMC article.
PURPOSE: This study aims to evaluate the efficacy and safety of a new combination treatment of vinorelbine and pyrotinib in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and provide higher level evidence for clinical practic …
PURPOSE: This study aims to evaluate the efficacy and safety of a new combination treatment of vinorelbine and pyrotinib in human epidermal …
New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization.
Ezelarab HAA, Ali TFS, Abbas SH, Sayed AM, Beshr EAM, Hassan HA. Ezelarab HAA, et al. Mol Divers. 2024 Apr;28(2):563-580. doi: 10.1007/s11030-023-10603-z. Epub 2023 Feb 15. Mol Divers. 2024. PMID: 36790582 Free PMC article.
Among these tested compounds, compounds 6f and 6g showed remarkable antiproliferative activity, specifically against leukemia and breast cancer cell lines. Compound 6f was the most promising antiproliferative agent against MCF-7 (human breast cancer) w …
Among these tested compounds, compounds 6f and 6g showed remarkable antiproliferative activity, specifically against leukemia and breast
Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice.
Bonomi M, Spada D, Baiocchi GL, Celotti A, Brighenti M, Grizzi G. Bonomi M, et al. Int J Mol Sci. 2024 Mar 30;25(7):3876. doi: 10.3390/ijms25073876. Int J Mol Sci. 2024. PMID: 38612688 Free PMC article. Review.
Gastroesophageal adenocarcinoma (GEA) is one of the principal causes of death related to cancer globally. Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor which is found to be overexpressed or amplified in approximately 20% of GEA …
Gastroesophageal adenocarcinoma (GEA) is one of the principal causes of death related to cancer globally. Human epidermal growth fact …
Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors.
Liu J, Yan S, Du J, Teng L, Yang R, Xu P, Tao W. Liu J, et al. Heliyon. 2024 Mar 6;10(6):e27531. doi: 10.1016/j.heliyon.2024.e27531. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38501021 Free PMC article. Review.
Tyrosine kinase inhibitors (TKIs) have become first-line drugs for cancer treatment. However, their clinical use is seriously hindered since many patients experience diarrhea after receiving TKIs. ...
Tyrosine kinase inhibitors (TKIs) have become first-line drugs for cancer treatment. However, their clinical use
Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
Wallace G, Kundalia R, Vallebuona E, Cao B, Kim Y, Forsyth P, Soyano A, Smalley I, Pina Y. Wallace G, et al. Breast Cancer Res. 2024 Mar 29;26(1):55. doi: 10.1186/s13058-024-01789-7. Breast Cancer Res. 2024. PMID: 38553702 Free PMC article.
BACKGROUND: Breast cancer-related leptomeningeal disease (BC-LMD) is a dire diagnosis for 5-8% of patients with breast cancer (BC). ...Prospective trials testing lapatinib and/or similar tyrosine kinase inhibitors, IT therapies, an …
BACKGROUND: Breast cancer-related leptomeningeal disease (BC-LMD) is a dire diagnosis for 5-8% of patients with breast
Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports.
Yanase Y, Bando H, Sato R, Matsuo T, Ueda A, Okazaki M, Hashimoto S, Iguchi-Manaka A, Hara H. Yanase Y, et al. J Med Case Rep. 2024 Mar 25;18(1):150. doi: 10.1186/s13256-024-04478-3. J Med Case Rep. 2024. PMID: 38523303 Free PMC article.
CASE REPORT: We report two cases of recurrent severe hypocalcemia occurring during chemotherapy for metastatic breast cancer with multiple bone metastases. Case 1: A 35-year-old Japanese woman developed metastases in the bone, liver, and ovaries during postoperative …
CASE REPORT: We report two cases of recurrent severe hypocalcemia occurring during chemotherapy for metastatic breast cancer w …
Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration.
Yu TW, Yamamoto H, Morita S, Fukushima R, Elbadawy M, Usui T, Sasaki K. Yu TW, et al. J Vet Med Sci. 2024 Mar 16;86(3):317-321. doi: 10.1292/jvms.23-0448. Epub 2024 Jan 29. J Vet Med Sci. 2024. PMID: 38281758 Free PMC article.
Lapatinib is an orally administered tyrosine kinase inhibitor used to treat human epidermal growth factor receptor 2 (HER2) -overexpressing breast cancers in humans. ...
Lapatinib is an orally administered tyrosine kinase inhibitor used to treat human epidermal growth factor receptor 2 (HER2) -o …
EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells.
Achounna AS, Ordaz-Rosado D, García-Quiroz J, Morales-Guadarrama G, Milo-Rocha E, Larrea F, Díaz L, García-Becerra R. Achounna AS, et al. Int J Mol Sci. 2024 Mar 9;25(6):3165. doi: 10.3390/ijms25063165. Int J Mol Sci. 2024. PMID: 38542136 Free PMC article.
HER2-positive breast cancer is associated with aggressive behavior and reduced survival rates. Calcitriol restores the antiproliferative activity of antiestrogens in estrogen receptor (ER)-negative breast cancer cells by re-expressing ERalpha. ...These …
HER2-positive breast cancer is associated with aggressive behavior and reduced survival rates. Calcitriol restores the antipro …
Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways.
Kheraldine H, Gupta I, Cyprian FS, Vranic S, Al-Farsi HF, Merhi M, Dermime S, Al Moustafa AE. Kheraldine H, et al. Cancer Cell Int. 2024 Mar 2;24(1):94. doi: 10.1186/s12935-023-03195-z. Cancer Cell Int. 2024. PMID: 38431613 Free PMC article.
BACKGROUND: Recent investigations have reported the benefits of using a tyrosine kinase inhibitor, dasatinib (DA), as well as programmed death-ligand 1 (PD-L1) inhibitors in the management of several solid tumors, including breast cancer. Nevert …
BACKGROUND: Recent investigations have reported the benefits of using a tyrosine kinase inhibitor, dasatinib (DA), as well as …
Liprin-α1 contributes to oncogenic MAPK signaling by counteracting ERK activity.
Pehkonen H, Filippou A, Väänänen J, Lindfors I, Vänttinen M, Ianevski P, Mäkelä A, Munne P, Klefström J, Toppila-Salmi S, Grénman R, Hagström J, Mäkitie AA, Karhemo PR, Monni O. Pehkonen H, et al. Mol Oncol. 2024 Mar;18(3):662-676. doi: 10.1002/1878-0261.13593. Epub 2024 Jan 24. Mol Oncol. 2024. PMID: 38264964 Free PMC article.
PTPRF interacting protein alpha 1 (PPFIA1) encodes for liprin-alpha1, a member of the leukocyte common antigen-related protein tyrosine phosphatase (LAR-RPTPs)-interacting protein family. Liprin-alpha1 localizes to adhesive and invasive structures in the periphery of ca
PTPRF interacting protein alpha 1 (PPFIA1) encodes for liprin-alpha1, a member of the leukocyte common antigen-related protein tyrosine
Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy.
Tomkins-Netzer O, Niederer R, Greenwood J, Fabian ID, Serlin Y, Friedman A, Lightman S. Tomkins-Netzer O, et al. Prog Retin Eye Res. 2024 Mar;99:101245. doi: 10.1016/j.preteyeres.2024.101245. Epub 2024 Jan 17. Prog Retin Eye Res. 2024. PMID: 38242492 Free article. Review.
New drugs used for chemotherapy (cytarabine, immune checkpoint inhibitors, BRAF inhibitors, EGFR inhibitors, bispecific anti-EGFR inhibitors, MET receptor inhibitors and Bruton tyrosine kinase inhibitors) can also cause diff …
New drugs used for chemotherapy (cytarabine, immune checkpoint inhibitors, BRAF inhibitors, EGFR inhibitors, bispecific …
Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study.
Liu S, Zhi W, Zhang L. Liu S, et al. J Cell Mol Med. 2024 Mar;28(5):e18008. doi: 10.1111/jcmm.18008. Epub 2023 Oct 27. J Cell Mol Med. 2024. PMID: 37891706 Free PMC article.
Our study aimes to evaluate the efficacy of anlotinib in the treatment of advanced metastatic breast cancer (MBC) after multiple lines of therapy. Patients included were treated with anlotinib for advanced MBC in the Affiliated Cancer Hospital of Zhengzhou Un …
Our study aimes to evaluate the efficacy of anlotinib in the treatment of advanced metastatic breast cancer (MBC) after multip …
Revealing Novel Source of Breast Cancer Inhibitors from Seagrass Enhalus acoroides: In Silico and In Vitro Studies.
Prajoko YW, Qhabibi FR, Gerardo TS, Kizzandy K, Tanjaya K, Willyanto SE, Permatasari HK, Surya R, Mayulu N, Taslim NA, Tjandrawinata RR, Syahputra RA, Tallei TE, Tsopmo A, Kim B, Kurniawan R, Nurkolis F. Prajoko YW, et al. Molecules. 2024 Feb 29;29(5):1082. doi: 10.3390/molecules29051082. Molecules. 2024. PMID: 38474594 Free PMC article.
Furthermore, the in-silico study was conducted using molecular docking simulations on the HER2, EGFR tyrosine kinase and HIF-1alpha protein receptor. Afterward, the antioxidant activity of E. acoroides metabolites was examined to ABTS, and the antiproliferative acti …
Furthermore, the in-silico study was conducted using molecular docking simulations on the HER2, EGFR tyrosine kinase and HIF-1 …
Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors.
Xu C, Wang Q, Wang D, Wang W, Fang W, Li Z, Liu A, Yu J, Zhong W, Wang Z, Zhang Y, Liu J, Zhang S, Cai X, Liu A, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Chen Y, Yuan J, Wang F, Jiang Z, Lin G, Huang L, Pu X, Lin R, Liu W, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Xue J, Guo H, Chu Q, Meng R, Wu J, Zhang R, Zhou J, Zhu Z, Li Y, Qiu H, Xia F, Lu Y, Chen X, Ge R, Dai E, Han Y, Pan W, Pang F, He Q, Huang J, Wang K, Wu F, Xu B, Wang L, Zhu Y, Lin L, Xie Y, Lin X, Cai J, Xu L, Li J, Jiao X, Li K, Wei J, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Huang J, Feng Y, Zhang Y, Sun P, Wang H, Ye M, Wang Z, Hao Y, Wang Z, Wan B, Lv D, Yang S, Kang J, Zhang J, Zhang C, Ou J, Shi L, Wang Y, Li B, Zhang Z, Li Z, Liu Z, Yang N, Wu L, Wang H, Jin G, Wang G, Wang J, Fang M, Fang Y, Li Y, Wang X, Zhang Y, Zhu X, Shen Y, Ma S, Wang B, Si L, Song Y, Lu Y, Chen J, Song Z. Xu C, et al. Glob Med Genet. 2024 Feb 27;11(1):86-99. doi: 10.1055/s-0044-1781457. eCollection 2024 Jan. Glob Med Genet. 2024. PMID: 38414979 Free PMC article. Review.
The incidence of NRG1 gene fusion varies across cancer types, with lung cancer being the most prevalent at 0.19 to 0.27%. CD74 and SLC3A2 are the most frequently observed fusion partners. ...Common treatment approaches involve pan-ERBB inhibitors, small molec …
The incidence of NRG1 gene fusion varies across cancer types, with lung cancer being the most prevalent at 0.19 to 0.27%. CD74 …
Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasis.
Ippolitov D, Lin YH, Spence J, Glogowska A, Thanasupawat T, Beiko J, Del Bigio MR, Xu X, Wang A, Calvo R, Kapoor A, Marugan JJ, Henderson MJ, Klonisch T, Hombach-Klonisch S. Ippolitov D, et al. bioRxiv [Preprint]. 2024 Feb 22:2024.02.19.581073. doi: 10.1101/2024.02.19.581073. bioRxiv. 2024. PMID: 38529509 Free PMC article. Preprint.
Brain metastasis of HER2+ breast cancer occurs in about 50% of all women with metastatic HER2+ breast cancer and confers poor prognosis for patients. Despite effective HER2-targeted treatments of peripheral HER2+ breast cancer with Trastu …
Brain metastasis of HER2+ breast cancer occurs in about 50% of all women with metastatic HER2+ breast cancer and …
Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma.
Repici A, Ardizzone A, De Luca F, Colarossi L, Prestifilippo A, Pizzino G, Paterniti I, Esposito E, Capra AP. Repici A, et al. Cells. 2024 Feb 19;13(4):361. doi: 10.3390/cells13040361. Cells. 2024. PMID: 38391974 Free PMC article. Review.
In the past, efforts to treat glioblastoma have mostly concentrated on customized treatment plans that target specific mutations such as epidermal growth factor receptor (EGFR) mutations, Neurotrophic Tyrosine Receptor Kinase (NTRK) fusions, or multiple receptors us …
In the past, efforts to treat glioblastoma have mostly concentrated on customized treatment plans that target specific mutations such as epi …
Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study.
Li C, Sun L, Liu Z, Sun H, Wang X, Yu Q, Yu Z. Li C, et al. Am J Cancer Res. 2024 Feb 15;14(2):869-879. doi: 10.62347/EMIK7909. eCollection 2024. Am J Cancer Res. 2024. PMID: 38455400 Free PMC article.
This retrospective study aimed to evaluate the effectiveness and safety of RC48 in HER2-positive metastatic breast cancer (MBC) in non-clinical trial settings. Eighty-one patients with metastatic HER2-positive BC who received RC48 in Shandong Cancer Hospital …
This retrospective study aimed to evaluate the effectiveness and safety of RC48 in HER2-positive metastatic breast cancer (MBC …
Superbinder based phosphoproteomic landscape revealed PRKCD_pY313 mediates the activation of Src and p38 MAPK to promote TNBC progression.
Deng Y, Hou Z, Li Y, Yi M, Wu Y, Zheng Y, Yang F, Zhong G, Hao Q, Zhai Z, Wang M, Ma X, Kang H, Ji F, Dong C, Liu H, Dai Z. Deng Y, et al. Cell Commun Signal. 2024 Feb 12;22(1):115. doi: 10.1186/s12964-024-01487-z. Cell Commun Signal. 2024. PMID: 38347536 Free PMC article.
Phosphorylation proteomics is the basis for the study of abnormally activated kinase signaling pathways in breast cancer, which facilitates the discovery of new oncogenic agents and drives the discovery of potential targets for early diagnosis and therapy of …
Phosphorylation proteomics is the basis for the study of abnormally activated kinase signaling pathways in breast cancer
Microvascular rarefaction caused by the NOTCH signaling pathway is a key cause of TKI-apatinib-induced hypertension and cardiac damage.
Wang W, Li G, Ma J, Fan X, Lu J, Sun Q, Yao J, He Q. Wang W, et al. Front Pharmacol. 2024 Feb 9;15:1346905. doi: 10.3389/fphar.2024.1346905. eCollection 2024. Front Pharmacol. 2024. PMID: 38405666 Free PMC article. Review.
With the advancement of tumour-targeted therapy technology, the survival of cancer patients has continued to increase, and cardiovascular events have gradually become an important cause of death in cancer patients. ...Moreover, the increase in the proportion of elde …
With the advancement of tumour-targeted therapy technology, the survival of cancer patients has continued to increase, and cardiovasc …
HER2-targeted therapies in cancer: a systematic review.
Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. Zhu K, et al. Biomark Res. 2024 Feb 2;12(1):16. doi: 10.1186/s40364-024-00565-1. Biomark Res. 2024. PMID: 38308374 Free PMC article. Review.
An increasing number of HER2-targeted drugs including specific monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs) have been approved by the U.S. ...The emergence of ADCs, has significantly transformed the treatment l …
An increasing number of HER2-targeted drugs including specific monoclonal antibodies, tyrosine kinase inhibitors (TKIs) …
Gefitinib induces anoikis in cervical cancer cells.
Jung BC, Woo SH, Kim SH, Kim YS. Jung BC, et al. BMB Rep. 2024 Feb;57(2):104-109. doi: 10.5483/BMBRep.2023-0225. BMB Rep. 2024. PMID: 38303562 Free PMC article.
Gefitinib exerts anticancer effects on various types of cancer, such as lung, ovarian, breast, and colon cancers. However, the therapeutic effects of gefitinib on cervical cancer and the underlying mechanisms remain unclear. ...It also induced detachment-indu …
Gefitinib exerts anticancer effects on various types of cancer, such as lung, ovarian, breast, and colon cancers. However, the …
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2024 Feb;200:107059. doi: 10.1016/j.phrs.2024.107059. Epub 2024 Jan 11. Pharmacol Res. 2024. PMID: 38216005 Free article. Review.
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century. ...The following seven drugs received FDA approval in 2023: capivasertib (HER2-positive …
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of …
From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
Cui Z, Zhai Z, Xie D, Wang L, Cheng F, Lou S, Zou F, Pan R, Chang S, Yao H, She J, Zhang Y, Yang X. Cui Z, et al. Front Pharmacol. 2024 Jan 31;15:1329409. doi: 10.3389/fphar.2024.1329409. eCollection 2024. Front Pharmacol. 2024. PMID: 38357305 Free PMC article.
Introduction: The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions has facilitated the development of precision oncology. ...NTRK gene expression has prognostic value in some cancer types, such as breast invasive carcinoma (BRCA). …
Introduction: The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions has facilitated the development of pr …
Integrated Proteogenomic Analysis Reveals Distinct Potentially Actionable Therapeutic Vulnerabilities in Triple-Negative Breast Cancer Subtypes.
Kaur P, Ring A, Porras TB, Zhou G, Lu J, Kang I, Lang JE. Kaur P, et al. Cancers (Basel). 2024 Jan 25;16(3):516. doi: 10.3390/cancers16030516. Cancers (Basel). 2024. PMID: 38339267 Free PMC article.
Triple-negative breast cancer (TNBC) is characterized by an aggressive clinical presentation and a paucity of clinically actionable genomic alterations. ...We found tighter coupling between proteome and genome in some genes that are predicted to be the targets of dr …
Triple-negative breast cancer (TNBC) is characterized by an aggressive clinical presentation and a paucity of clinically actio …
Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.
Kook E, Chun KS, Kim DH. Kook E, et al. Int J Mol Sci. 2024 Jan 25;25(3):1450. doi: 10.3390/ijms25031450. Int J Mol Sci. 2024. PMID: 38338729 Free PMC article. Review.
Src family kinases (SFKs) are non-receptor tyrosine kinases that are recognized as proto-oncogenic products. Among SFKs, YES1 is frequently amplified and overexpressed in a variety of human tumors, including lung, breast, ovarian, and skin cancers. ...Recent finding …
Src family kinases (SFKs) are non-receptor tyrosine kinases that are recognized as proto-oncogenic products. Among SFKs, YES1 is freq …
Co-delivery of lapatinib and 5-fluorouracil transfersomes using transpapillary iontophoresis for breast cancer therapy.
Fernandes NB, Velagacherla V, Spandana KJ, N B, Mehta CH, Gadag S, Sabhahit JN, Nayak UY. Fernandes NB, et al. Int J Pharm. 2024 Jan 25;650:123686. doi: 10.1016/j.ijpharm.2023.123686. Epub 2023 Dec 7. Int J Pharm. 2024. PMID: 38070658 Free article.
Combination chemotherapy, involving the intervention of two or more anti-neoplastic agents has been the cornerstone in breast cancer treatment, owing to the applications it holds in contrast to the mono-therapy approach. This research predominantly focussed on provi …
Combination chemotherapy, involving the intervention of two or more anti-neoplastic agents has been the cornerstone in breast canc
Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs.
Guy M, Teixeira A, Shrier A, Meschter C, Bolognese J, Chaturvedi P. Guy M, et al. PLoS One. 2024 Jan 24;19(1):e0282769. doi: 10.1371/journal.pone.0282769. eCollection 2024. PLoS One. 2024. PMID: 38265977 Free PMC article.
Targeted therapies have increased cancer therapy-related diarrhea (CTD) burden, with high incidence and/or severity of diarrhea for some agents that inhibit epidermal growth factor receptor and receptor tyrosine kinases. Neratinib is a pan-HER tyrosine kin
Targeted therapies have increased cancer therapy-related diarrhea (CTD) burden, with high incidence and/or severity of diarrhea for s …
Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials.
Wang J, Yu Y, Lin Q, Zhang J, Song C. Wang J, et al. J Cancer Res Clin Oncol. 2024 Jan 20;150(1):21. doi: 10.1007/s00432-023-05530-3. J Cancer Res Clin Oncol. 2024. PMID: 38244085 Free PMC article.
PURPOSE: The numerous first-line treatment regimens for human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC) necessitate a comprehensive evaluation to inform clinical decision-making. ...Regarding PFS and ORR, the combination of tras …
PURPOSE: The numerous first-line treatment regimens for human epidermal growth factor receptor 2 (HER2)-positive advanced breast c
Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.
Guo L, Cheng H, Liu J, Shao W, Luo L, Zheng W, Sun S, Kong D, Chen C. Guo L, et al. BMC Med Genomics. 2024 Jan 19;17(1):25. doi: 10.1186/s12920-023-01762-x. BMC Med Genomics. 2024. PMID: 38243282 Free PMC article.
BACKGROUND: Breast cancer is the second leading cause of cancer-related death in women, and drug resistance during treatment is a major challenge. ...Here we applied whole-exome sequencing (WES) to clarify resistant rules to Herceptin and tyrosine k
BACKGROUND: Breast cancer is the second leading cause of cancer-related death in women, and drug resistance during trea …
4″-Alkyl EGCG Derivatives Induce Cytoprotective Autophagy Response by Inhibiting EGFR in Glioblastoma Cells.
Singh S, Ghosh P, Roy R, Behera A, Sahadevan R, Kar P, Sadhukhan S, Sonawane A. Singh S, et al. ACS Omega. 2024 Jan 3;9(2):2286-2301. doi: 10.1021/acsomega.3c06110. eCollection 2024 Jan 16. ACS Omega. 2024. PMID: 38250397 Free PMC article.
Epidermal growth factor receptor (EGFR)-targeted therapy has been proven vital in the last two decades for the treatment of multiple cancer types, including nonsmall cell lung cancer, glioblastoma, breast cancer and head and neck squamous cell carcinom …
Epidermal growth factor receptor (EGFR)-targeted therapy has been proven vital in the last two decades for the treatment of multiple canc
Exploring the Spectrum of VEGF Inhibitors' Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice.
Santorsola M, Capuozzo M, Nasti G, Sabbatino F, Di Mauro A, Di Mauro G, Vanni G, Maiolino P, Correra M, Granata V, Gualillo O, Berretta M, Ottaiano A. Santorsola M, et al. Cancers (Basel). 2024 Jan 13;16(2):350. doi: 10.3390/cancers16020350. Cancers (Basel). 2024. PMID: 38254839 Free PMC article. Review.
These conditions encompass a range of advanced neoplasms, such as colorectal cancer, non-small cell lung cancer, renal cancer, ovarian cancer, and others, along with ocular diseases. ...VEGFi can be broadly categorized into two groups: antibodie …
These conditions encompass a range of advanced neoplasms, such as colorectal cancer, non-small cell lung cancer, renal …
Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer.
Tan YQ, Chiou YS, Guo H, Zhang S, Huang X, Dukanya D, Kumar AM, Basappa S, Liu S, Zhu T, Basappa B, Pandey V, Lobie PE. Tan YQ, et al. NPJ Precis Oncol. 2024 Jan 10;8(1):8. doi: 10.1038/s41698-023-00489-3. NPJ Precis Oncol. 2024. PMID: 38200104 Free PMC article.
Additionally, combinatorial oncology compound library screening demonstrated that NCK synergized with tyrosine kinase inhibitors (TKIs), specifically OSI-930 or Crizotinib in reducing cell viability and promoting apoptosis of TNBC cells. ...
Additionally, combinatorial oncology compound library screening demonstrated that NCK synergized with tyrosine kinase inhib
Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.
Sun K, Wang X, Zhang H, Lin G, Jiang R. Sun K, et al. Cancer Control. 2024 Jan-Dec;31:10732748241278039. doi: 10.1177/10732748241278039. Cancer Control. 2024. PMID: 39159918 Free PMC article. Review.
Breast cancer has the highest incidence among female malignancies, significantly impacting women's health. ...This review aims to elucidate management approaches for diarrhea induced by HER2 tyrosine kinase inhibitors during breast can
Breast cancer has the highest incidence among female malignancies, significantly impacting women's health. ...This review aims
Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations.
Mikuteit M, Zschäbitz S, Autenrieth M, Weichert W, Hartmann A, Steffens S, Erlmeier F. Mikuteit M, et al. Oncology. 2024;102(6):503-509. doi: 10.1159/000535473. Epub 2023 Dec 1. Oncology. 2024. PMID: 38043528 Free article.
A nectin-4-directed antibody drug conjugate, enfortumab vedotin-ejf, has recently been approved for treatment in urothelial cancer and is currently under investigation in other tumor entities such as breast, lung, and prostate cancer. In non-clear cell renal …
A nectin-4-directed antibody drug conjugate, enfortumab vedotin-ejf, has recently been approved for treatment in urothelial cancer an …
Progress of non-small-cell lung cancer with ROS1 rearrangement.
Yang X, Tang Z, Li J, Jiang J, Liu Y. Yang X, et al. Front Mol Biosci. 2023 Dec 22;10:1238093. doi: 10.3389/fmolb.2023.1238093. eCollection 2023. Front Mol Biosci. 2023. PMID: 38187090 Free PMC article. Review.
ROS1 rearrangement is found in 0.9%-2.6% of people with non-small-cell lung cancers (NSCLCs). Tyrosine kinase inhibitors (TKIs) target ROS1 and can block tumor growth and provide clinical benefits to patients. ...
ROS1 rearrangement is found in 0.9%-2.6% of people with non-small-cell lung cancers (NSCLCs). Tyrosine kinase inhibitors
The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib.
Chen S, Li X, Li Y, He X, Bryant M, Qin X, Li F, Seo JE, Guo X, Mei N, Guo L. Chen S, et al. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099. Toxicol Sci. 2023. PMID: 37788138 Free PMC article.
Lapatinib, an oral tyrosine kinase inhibitor used as a first-line treatment for HER2-positive breast cancer, has been reported to be associated with hepatotoxicity; however, the underlying mechanisms remain unclear. ...
Lapatinib, an oral tyrosine kinase inhibitor used as a first-line treatment for HER2-positive breast cancer, has …
Systemic Therapies for HER2-Positive Advanced Breast Cancer.
Angelis V, Okines AFC. Angelis V, et al. Cancers (Basel). 2023 Dec 20;16(1):23. doi: 10.3390/cancers16010023. Cancers (Basel). 2023. PMID: 38201451 Free PMC article. Review.
These include novel, more potent selective HER2 tyrosine kinase inhibitors (TKIs); new anti-HER2 antibody-drug conjugates; and dual epitope targeting antibodies, with more advanced pharmacological properties and higher affinity. ...In this article, we review …
These include novel, more potent selective HER2 tyrosine kinase inhibitors (TKIs); new anti-HER2 antibody-drug conjugat …
Therapeutic targeting of p90 ribosomal S6 kinase.
Wright EB, Lannigan DA. Wright EB, et al. Front Cell Dev Biol. 2023 Dec 19;11:1297292. doi: 10.3389/fcell.2023.1297292. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 38169775 Free PMC article. Review.
The Serine/Threonine protein kinase family, p90 ribosomal S6 kinases (RSK) are downstream effectors of extracellular signal regulated kinase 1/2 (ERK1/2) and are activated in response to tyrosine kinase receptor or G-protein coupled receptor signaling. …
The Serine/Threonine protein kinase family, p90 ribosomal S6 kinases (RSK) are downstream effectors of extracellular signal regulated …
Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada.
Gambaro K, Groleau M, McNamara S, Awan A, Salem M, Abdelsalam M, St-Hilaire E, Vincent F, Carrier J, MacKay H, Provencher L, Boudreau D, Hamilou Z, Saad F, Ferrario C, Batist G, Marques M. Gambaro K, et al. J Pharm Pharm Sci. 2023 Dec 13;26:12078. doi: 10.3389/jpps.2023.12078. eCollection 2023. J Pharm Pharm Sci. 2023. PMID: 38152647 Free PMC article.
There is an increasing demand for real-world data pertaining to the usage of cancer treatments, especially in settings where no standard treatment is specifically recommended. This study presents the first real-world analysis of third-line treatment patterns in HER2-positi …
There is an increasing demand for real-world data pertaining to the usage of cancer treatments, especially in settings where no stand …
Busting the Breast Cancer with AstraZeneca's Gefitinib.
Chemmalar S, Intan Shameha AR, Che Abdullah CA, Ab Razak NA, Yusof LM, Ajat M, Chan KW, Abu Bakar Zakaria MZ. Chemmalar S, et al. Adv Pharmacol Pharm Sci. 2023 Dec 4;2023:8127695. doi: 10.1155/2023/8127695. eCollection 2023. Adv Pharmacol Pharm Sci. 2023. PMID: 38090376 Free PMC article. Review.
Breast cancer is the most common cancer diagnosed in women, and in 2020, there were 684, 996 deaths due to this disease. ...Gefitinib (GEF), a tyrosine kinase inhibitor of EGFR1, possesses a vast potential for treatment against breast
Breast cancer is the most common cancer diagnosed in women, and in 2020, there were 684, 996 deaths due to this disease
Management of Brain Metastases: A Review of Novel Therapies.
Bellur S, Khosla AA, Ozair A, Kotecha R, McDermott MW, Ahluwalia MS. Bellur S, et al. Semin Neurol. 2023 Dec;43(6):845-858. doi: 10.1055/s-0043-1776782. Epub 2023 Nov 27. Semin Neurol. 2023. PMID: 38011864 Free article. Review.
Brain metastases (BMs) represent the most common intracranial tumors in adults, and most commonly originate from lung, followed by breast, melanoma, kidney, and colorectal cancer. Management of BM is individualized based on the size and number of brain metastases, t …
Brain metastases (BMs) represent the most common intracranial tumors in adults, and most commonly originate from lung, followed by breast
Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody.
Liu B, Xie N, Tian C, Feng R, Hu ZY, Li J, Liu L, Xiao H, Yang X, Zeng M, Wu H, Lu J, Gao J, Hu X, Cao M, Shui Z, Tang Y, Wu T, Ouyang Q. Liu B, et al. Breast. 2023 Dec;72:103597. doi: 10.1016/j.breast.2023.103597. Epub 2023 Nov 1. Breast. 2023. PMID: 37944341 Free PMC article.
The most frequently employed treatment strategy was inetetamab + chemotherapy (49/141, 34.8 %), followed by inetetamab + HER2-tyrosine kinase inhibitors (HER2-TKIs) + chemotherapy, inetetamab + pertuzumab + chemotherapy, inetetamab + endocrine treatment and i …
The most frequently employed treatment strategy was inetetamab + chemotherapy (49/141, 34.8 %), followed by inetetamab + HER2-tyrosine
AXL - a new player in resistance to HER2 blockade.
Adam-Artigues A, Arenas EJ, Arribas J, Prat A, Cejalvo JM. Adam-Artigues A, et al. Cancer Treat Rev. 2023 Dec;121:102639. doi: 10.1016/j.ctrv.2023.102639. Epub 2023 Oct 7. Cancer Treat Rev. 2023. PMID: 37864955 Free article. Review.
Preclinical studies show that AXL drives anti-HER2 resistance and metastasis through dimerization with HER2 and activation of downstream pathways in breast cancer. Moreover, AXL inhibition restores response to HER2 blockade in vitro and in vivo. Limited data in gast …
Preclinical studies show that AXL drives anti-HER2 resistance and metastasis through dimerization with HER2 and activation of downstream pat …
Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer.
Takatsu F, Suzawa K, Tomida S, Thu YM, Sakaguchi M, Toji T, Ohki M, Tsudaka S, Date K, Matsuda N, Iwata K, Zhu Y, Nakata K, Shien K, Yamamoto H, Nakayama A, Okazaki M, Sugimoto S, Toyooka S. Takatsu F, et al. J Mol Med (Berl). 2023 Dec;101(12):1603-1614. doi: 10.1007/s00109-023-02384-7. Epub 2023 Oct 13. J Mol Med (Berl). 2023. PMID: 37831111 Free article.
Cancer-associated fibroblasts (CAFs) are important components in the tumor microenvironment, and we sought to identify effective therapeutic targets in CAFs for non-small cell lung cancer (NSCLC). ...RNA sequencing analysis was performed to investigate the different
Cancer-associated fibroblasts (CAFs) are important components in the tumor microenvironment, and we sought to identify effective ther
Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines.
Son S, Elkamhawy A, Gul AR, Al-Karmalawy AA, Alnajjar R, Abdeen A, Ibrahim SF, Alshammari SO, Alshammari QA, Choi WJ, Park TJ, Lee K. Son S, et al. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2202358. doi: 10.1080/14756366.2023.2202358. J Enzyme Inhib Med Chem. 2023. PMID: 37096560 Free PMC article.
Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) protein tyrosine kinases co-expressed in various cancers such as ovarian, breast, colon, and prostate subtypes. ...Compound 9f also showed high selectivity profile when teste …
Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) protein tyrosine kinases co-expressed in …
The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
Nakano K. Nakano K. Int J Mol Sci. 2023 Nov 27;24(23):16823. doi: 10.3390/ijms242316823. Int J Mol Sci. 2023. PMID: 38069146 Free PMC article. Review.
Human epidermal growth factor receptor 2 (HER2), coded by the proto-oncogene ERBB, is known to be mutated or amplified in various malignant diseases, and many HER2-targeted therapies (including monoclonal antibodies and low-molecular-weight tyrosine kinase inhibi
Human epidermal growth factor receptor 2 (HER2), coded by the proto-oncogene ERBB, is known to be mutated or amplified in various malignant …
Evolution of the Management of Brain Metastases: A Bibliometric Analysis.
Burney IA, Aal Hamad AH, Hashmi SFA, Ahmad N, Pervez N. Burney IA, et al. Cancers (Basel). 2023 Nov 24;15(23):5570. doi: 10.3390/cancers15235570. Cancers (Basel). 2023. PMID: 38067273 Free PMC article. Review.
Most randomized trials reported on brain metastases management from unselected tumors (49), lung cancer (47), or breast cancer (11). In the last 5 years (2017 to 2022), management of brain metastasis has moved on from WBRT, the use of chemotherapy, and radio- …
Most randomized trials reported on brain metastases management from unselected tumors (49), lung cancer (47), or breast can
Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects.
Chen L, Liu CC, Zhu SY, Ge JY, Chen YF, Ma D, Shao ZM, Yu KD. Chen L, et al. JCI Insight. 2023 Nov 22;8(22):e172366. doi: 10.1172/jci.insight.172366. JCI Insight. 2023. PMID: 37991016 Free PMC article.
To provide complementary information and reveal the molecular characteristics and therapeutic insights of HER2-low breast cancer, we performed this multiomics study of hormone receptor-negative (HR-) and HER2-low breast cancer, also known as HER2-low t …
To provide complementary information and reveal the molecular characteristics and therapeutic insights of HER2-low breast cancer
Long-term outcome after surgical resection of non-high-risk gastrointestinal stromal tumours without adjuvant therapy.
Berndsen M, Renberg S, Hølmebakk T, Hancke E, Puls F, Karlsson F, Stoldt S, Bjerkehagen B, Haglund de Flon F, Muth A, Papakonstantinou A, Boye K, Lindskog S. Berndsen M, et al. Br J Surg. 2023 Nov 9;110(12):1857-1862. doi: 10.1093/bjs/znad309. Br J Surg. 2023. PMID: 37758514 Free PMC article.
High-risk patients and those treated with tyrosine kinase inhibitors were excluded. The remaining 649 patients were included in the present analysis: 118 with very low-, 381 with low-, and 150 with intermediate-risk GISTs. ...Only 1.2 per cent of the patients …
High-risk patients and those treated with tyrosine kinase inhibitors were excluded. The remaining 649 patients were inc …
Molecular Imaging of Breast Cancer.
Krishnaraju VS, Singh H, Hall LT, Takalkar AM, Mittal BR. Krishnaraju VS, et al. In: Hall LT, editor. Molecular Imaging and Therapy [Internet]. Brisbane (AU): Exon Publications; 2023 Nov 8. Chapter 6. In: Hall LT, editor. Molecular Imaging and Therapy [Internet]. Brisbane (AU): Exon Publications; 2023 Nov 8. Chapter 6. PMID: 38190472 Free Books & Documents. Review.
Breast cancer is one of the most common types of malignancy, with an increasing incidence worldwide. ...Non-FDG radiopharmaceuticals also have a potential role in breast cancer imaging. These include agents that target hormonal and tyrosine k
Breast cancer is one of the most common types of malignancy, with an increasing incidence worldwide. ...Non-FDG radiopharmaceu
New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
Fakhry MM, Mattar AA, Alsulaimany M, Al-Olayan EM, Al-Rashood ST, Abdel-Aziz HA. Fakhry MM, et al. Molecules. 2023 Nov 6;28(21):7455. doi: 10.3390/molecules28217455. Molecules. 2023. PMID: 37959874 Free PMC article.
These eighteen derivatives have been designed as anticipated EGFR/HER2 dual inhibitors. The efficacy of the developed compounds in inhibiting cell proliferation was assessed using the breast cancer MCF-7 cell line. ...
These eighteen derivatives have been designed as anticipated EGFR/HER2 dual inhibitors. The efficacy of the developed compounds in in …
Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
Biali ME, Auvity S, Cisternino S, Smirnova M, Hacker M, Zeitlinger M, Mairinger S, Tournier N, Bauer M, Langer O. Biali ME, et al. Mol Pharm. 2023 Nov 6;20(11):5877-5887. doi: 10.1021/acs.molpharmaceut.3c00715. Epub 2023 Oct 26. Mol Pharm. 2023. PMID: 37883694 Free PMC article.
P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are two ATP-binding cassette efflux transporters that are coexpressed at the human blood-brain barrier (BBB) and blood-retina barrier (BRB). While pharmacological inhibition of P-gp and/or BCRP result …
P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are two ATP-binding cassette efflux transporters that are co …
Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR.
Kim S, Park JM, Park S, Jung E, Ko D, Park M, Seo J, Nam KD, Kang YK, Lee K, Farrand L, Kim YJ, Kim JY, Seo JH. Kim S, et al. J Exp Clin Cancer Res. 2023 Nov 4;42(1):292. doi: 10.1186/s13046-023-02866-z. J Exp Clin Cancer Res. 2023. PMID: 37924112 Free PMC article.
BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by aggressive growth and a high propensity for recurrence and metastasis. ...Although the development of new c-MET inhibitors and the emergence of 3(rd)-generation EGFR inhibitors repres …
BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by aggressive growth and a high propensity for recurrence an …
Molecular Characteristics and Therapeutic Vulnerabilities of Claudin-low Breast Cancers Derived from Cell Line Models.
Voutsadakis IA. Voutsadakis IA. Cancer Genomics Proteomics. 2023 Nov-Dec;20(6):539-555. doi: 10.21873/cgp.20404. Cancer Genomics Proteomics. 2023. PMID: 37889067 Free PMC article.
MATERIALS AND METHODS: Breast cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) were assessed for mRNA suppression of claudins and mRNA expression of ER and ERBB2 (the gene encoding HER2). ...Potential drug sensitivities revealed in the drug scr …
MATERIALS AND METHODS: Breast cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) were assessed for mRNA su …
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer.
Stanowicka-Grada M, Senkus E. Stanowicka-Grada M, et al. Curr Treat Options Oncol. 2023 Nov;24(11):1633-1650. doi: 10.1007/s11864-023-01137-5. Epub 2023 Oct 25. Curr Treat Options Oncol. 2023. PMID: 37878202 Free PMC article. Review.
In recent years, a number of new anti-HER2 therapies have been developed, and their approvals offer new therapeutic options for patients with advanced HER2-positive breast cancer. At present, HER2 pathway blocking drugs used in the treatment of metastatic breast
In recent years, a number of new anti-HER2 therapies have been developed, and their approvals offer new therapeutic options for patients wit …
Intratumoral heterogeneity after targeted therapy in murine cancer models with differing degrees of malignancy.
Gerwing M, Hoffmann E, Geyer C, Helfen A, Maus B, Schinner R, Wachsmuth L, Heindel W, Eisenblaetter M, Faber C, Wildgruber M. Gerwing M, et al. Transl Oncol. 2023 Nov;37:101773. doi: 10.1016/j.tranon.2023.101773. Epub 2023 Sep 2. Transl Oncol. 2023. PMID: 37666208 Free PMC article.
INTRODUCTION: Conventional morphologic and volumetric assessment of treatment response is not suitable for adequately assessing responses to targeted cancer therapy. The aim of this study was to evaluate changes in tumor composition after targeted therapy in murine models …
INTRODUCTION: Conventional morphologic and volumetric assessment of treatment response is not suitable for adequately assessing responses to …
HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer.
Majumder A. Majumder A. Cells. 2023 Oct 25;12(21):2517. doi: 10.3390/cells12212517. Cells. 2023. PMID: 37947595 Free PMC article. Review.
Human epidermal growth factor receptor 3 (HER3) is the only family member of the EGRF/HER family of receptor tyrosine kinases that lacks an active kinase domain (KD), which makes it an obligate binding partner with other receptors for its oncogenic role. ...HER3 has …
Human epidermal growth factor receptor 3 (HER3) is the only family member of the EGRF/HER family of receptor tyrosine kinases that la …
Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
Nagasaka M, Zhang SS, Baca Y, Xiu J, Nieva J, Vanderwalde A, Swensen JJ, Spetzler D, Korn WM, Raez LE, Liu SV, Ou SI. Nagasaka M, et al. BMC Cancer. 2023 Oct 18;23(1):1000. doi: 10.1186/s12885-023-11457-2. BMC Cancer. 2023. PMID: 37853341 Free PMC article.
BACKGROUND: Two ROS1 tyrosine kinase inhibitors have been approved for ROS1 fusion positive (ROS1+) non-small cell lung cancer (NSCLC) tumors. ...ROS1+ NSCLC constituted 78.8% of the ROS1+ solid malignancies, follow by glioblastoma (GBM) (6.9%), and …
BACKGROUND: Two ROS1 tyrosine kinase inhibitors have been approved for ROS1 fusion positive (ROS1+) non-small cell lung …
Dose-sparing effect of lapatinib co-administered with a high-fat enteral nutrition emulsion: preclinical pharmacokinetic study.
Zhu J, Xu G, Yang D, Song Y, Tong Y, Kong S, Ding H, Fang L. Zhu J, et al. PeerJ. 2023 Oct 9;11:e16207. doi: 10.7717/peerj.16207. eCollection 2023. PeerJ. 2023. PMID: 37842056 Free PMC article.
BACKGROUND: Lapatinib is an oral small-molecule tyrosine kinase inhibitor indicated for advanced or metastatic HER2-positive breast cancer. ...
BACKGROUND: Lapatinib is an oral small-molecule tyrosine kinase inhibitor indicated for advanced or metastatic HER2-positive …
Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial.
Yan M, Niu L, Lv H, Zhang M, Wang J, Liu Z, Chen X, Lu Z, Zhang C, Zeng H, Zhao S, Feng Y, Sun H, Li H. Yan M, et al. Nat Commun. 2023 Oct 7;14(1):6272. doi: 10.1038/s41467-023-41955-7. Nat Commun. 2023. PMID: 37805496 Free PMC article. Clinical Trial.
CDK4/6 inhibitors have shown a synergistic effect with anti-HER2 therapy in hormone receptor (HR)-positive and HER2-positive breast cancer (BC). In this phase 2 study (NCT04293276), we aim to evaluate a dual-oral regimen of CDK4/6 inhibitor dalpiciclib combin …
CDK4/6 inhibitors have shown a synergistic effect with anti-HER2 therapy in hormone receptor (HR)-positive and HER2-positive breas
Neratinib for HER2-positive breast cancer with an overlooked option.
Guo L, Shao W, Zhou C, Yang H, Yang L, Cai Q, Wang J, Shi Y, Huang L, Zhang J. Guo L, et al. Mol Med. 2023 Oct 6;29(1):134. doi: 10.1186/s10020-023-00736-0. Mol Med. 2023. PMID: 37803271 Free PMC article. Review.
Positive human epidermal growth factor receptor 2 (HER2) expression is associated with an increased risk of metastases especially those to the brain in patients with advanced breast cancer (BC). Neratinib as a tyrosine kinase inhibitor can prevent the …
Positive human epidermal growth factor receptor 2 (HER2) expression is associated with an increased risk of metastases especially those to t …